

## Symptom Management Guidelines Bibliography

TABLE OF CONTENTS	
Symptom:	Page(s)
Acneiform Rash	2
Anorexia and Cachexia	2 – 6
Constipation	6 – 8
Diarrhea (Cancer-Related)	8 – 11
Dyspnea (Breathlessness)	11 – 14
Fatigue	14 – 16
Fever and Neutropenia	16 – 20
Intimacy and Sexuality	20 – 22
Lymphedema	22 – 26
Malignant Wounds	26 – 28
Nausea and Vomiting	28 – 30
Oral Mucositis (Stomatitis)	30 – 33
Pain	33 – 35
Palmar-Plantar Erythrodysesthesia (PPE)	35 – 39
Peripheral Neuropathy (Chemotherapy-Induced)	39 – 41
Radiation Dermatitis	41 – 46
Sleep-Wake Disturbances	46 – 48
Xerostomia	48 – 49

**Please note:**

**The links shown throughout this bibliography may not be functional as changes may have occurred to the primary sources. You may contact the Education Resource Nurse Team for assistance: [nursinged@bccancer.bc.ca](mailto:nursinged@bccancer.bc.ca)**

(Please note that this resource line for healthcare professionals is NOT for urgent inquiries, it is monitored intermittently Monday - Friday from 8:00 AM - 4:00 PM)

Updated: May, 2019

## Acneiform Rash

Melosky B., Leighl, N.B., Rothenstein, J., Sangha, R., Stewart, D., Papp, K. (2015). Management of EGFR TKI-induced dermatologic adverse events. *Current Oncology*, 22(2): 123–132.

Payne, A.S. Savarese, D. MF., (2015). Cutaneous complications for molecularly targeted and other biologic agents used for cancer therapy. Up-To-Date. Retrieved on Sep 15, 2016 from:

[http://www.uptodate.com/contents/cutaneous-complications-of-molecularly-targeted-therapy-and-other-biologic-agents-used-for-cancer-therapy?source=search\\_result&search=cutaneous+complications&selectedTitle=2%7E150](http://www.uptodate.com/contents/cutaneous-complications-of-molecularly-targeted-therapy-and-other-biologic-agents-used-for-cancer-therapy?source=search_result&search=cutaneous+complications&selectedTitle=2%7E150)

Cancer.Net Editorial Board. (2012). Skin Reactions to Targeted Therapy and Immunotherapy. American Society of Clinical Oncology (ASCO). Cancer.Net Articles. Retrieved on Sep 15, 2016 from: <http://www.cancer.net/navigating-cancer-care/side-effects/skin-reactions-targeted-therapy-and-immunotherapy>.

Melosky, B. Anderson. H., et al. Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer. *Journal of Clinical Oncology*. 2015

## Anorexia and Cachexia

Adams, L., Cunningham, R., Caruso, R.A., Norling, M., & Shepard, N. Anorexia. Putting Evidence into Practice. Pittsburgh, PA, Oncology Nursing Society. 2008: 1-6 [cited 2008, Aug 28]. Available from: [www.ons.org/outcomes](http://www.ons.org/outcomes)

American Dietetic Association. Critical Illness Evidence-Based Nutrition Practice Guideline. 2006, 2007, May 27:7. [cited 2008, Aug 28]. Available from: <http://www.adaevidencelibrary.com/topic.cfm?cat=2799>

American Dietetic Association. Adult Weight Management Evidence Based Nutrition Practice Guideline. 2006, 2007, May 27:5. [cited 2008, Aug 28]. Available from: <http://www.adaevidencelibrary.com/topic.cfm?cat=2798>

American Dietetic Association. ADA Oncology Evidence-based Nutrition Practice Guideline. 2007, 2008, May 27:6. [cited 2008, Aug 28]. Available from: <http://www.adaevidencelibrary.com/topic.cfm?cat=3250>

American Society for Parenteral and Enteral Nutrition. (2011). Definition of terms. Retrieved May 14, 2013 from: <https://www.nutritioncare.org/lcontent.aspx?id=546>

Basch, E., et al. Patient online self-reporting of toxicity symptoms during chemotherapy. *Journal of Clinical Oncology*, 2005; 23(15): 3552-3561. The American Society of Clinical Oncology, Alexandria, VA.

BC Cancer Nursing. (2014). Parenteral Nutrition, Administration of.

Berenstein, E.G., & Ortis, Z. Megestrol acetate for treatment of anorexia-cachexia syndrome (Review). 2008; 1, Hohn Wiley & Sons Ltd., Hoboken, NJ.

Biesemeier, C.W., & Elliott, L.G. ADA Evidence Analysis Library: ADA Oncology Evidence-based Nutrition Practice Guideline. 2008, 2005, May 27:6. American Dietetic Association. Available from: <http://www.adaevidencelibrary.com/topic.cfm?cat=3250>

- Biesemeier, C.W., & Elliott, L.G. ADA Evidence-based Nutrition Practice Guideline – Guideline overview. 2008, May 27:2. American Dietetic Association. Available from: <http://www.adaevidencelibrary.com/topic.cfm?cat=2871&library=EBG>
- Brown, J.K. (2002). A systematic review of the evidence on symptom management of cancer-related anorexia and cachexia. *Oncology Nursing Forum*, 29(3), 517-530.
- Bruera, E. and Arnold, R. (2017). Palliative care: Assessment and management of anorexia and cachexia. Retrieved from <https://www.uptodate.com/contents/palliative-care-assessment-and-management-of-anorexia-and-cachexia>
- Bruera, E., & Dev, R. (2012). Palliative Care: Overview of managing common non-pain symptoms. In: D.S. Basow (Ed.). *UpToDate*. Waltham, MA: UpToDate. Retrieved January 10, 2013 from: [http://www.uptodate.com/contents/overview-of-managing-common-non-pain-symptoms-in-palliative-care?source=search\\_result&search=Palliative+care%3A+Overview+of+managing+common+non-pain+symptoms&selectedTitle=1~150](http://www.uptodate.com/contents/overview-of-managing-common-non-pain-symptoms-in-palliative-care?source=search_result&search=Palliative+care%3A+Overview+of+managing+common+non-pain+symptoms&selectedTitle=1~150)
- Cancer Care Ontario. (2012). Symptom management guide-to-practice: Loss of Appetite. Retrieved March 22, 2013 from: [https://www.cancercare.on.ca/CCO\\_DrugFormulary/Pages/FileContent.aspx?fileId=154802](https://www.cancercare.on.ca/CCO_DrugFormulary/Pages/FileContent.aspx?fileId=154802)
- Cancer Care Ontario. (2016). How to Manage Your Loss of Appetite. Retrieved from <https://archive.cancercare.on.ca/common/pages/UserFile.aspx?fileId=357465>
- Cerchietti, L.C.A., et al. (2004). Effects of celecoxib, medroxyprogesterone and dietary intervention on systemic syndromes in patients with advanced lung adenocarcinoma: A pilot study. *Journal of Pain and Symptom Management*. 27:1, Elsevier Inc., New York, NY.
- Cope, D.G. (2002). Management of anorexia, cachexia and weight loss in patients with advanced cancer. *Clinical Journal of Oncology Nursing*, 6(4), 241-242.
- Cunningham, R.S. The Anorexia-Cachexia Syndrome. In: Yarbro CH, Frogge MH, Goodman M, editors. *Cancer Symptom Management*. 3rd ed. Sudbury, Massachusetts: Jones and Bartlett Publishers; 2004. p. 137-167.
- Cunningham, R.S. Measuring oncology nursing-sensitive patient outcomes: evidenced-based summary. 2005, 2008, May; 6 [cited 2008, Aug 28]:15. *Oncology Nursing Society*, Pittsburg, PA. Available from: <http://www.ons.org/outcomes/measure/nutrition.shtml>
- Cunningham, R.S., & Hullmann, M.B. Nutritional Disturbances. In Yarbro CH, Frogge MH, Goodman M, editors. *Cancer Nursing Principles and Practice*. 6<sup>th</sup> ed. Sudbury, Massachusetts: Jones and Bartlett Publishers; 2005. p. 761-790.
- Dahele, M., Fearon, Kenneth, C.H. Research methodology: Cancer cachexia syndrome. *Palliative Medicine*, 2004; 18(5):409-417. Edward Arnold (Publishers) Ltd., London England.
- Delano, M.J., & Moldawer, L.L. The origins of cachexia in acute and chronic inflammatory diseases. *Nutrition in Clinical Practice*, 2006; 21:68-81, American Society for Parenteral and Enteral Nutrition, Silver Spring, MD.
- e-CPS [Internet]. Ottawa (ON): Canadian Pharmacists Association; c2014 . Available from: <http://www.e-cps.ca>.
- Elliott, L., Molseed, L.L., & Davis, P. (2006). *The clinical guide to oncology nutrition* (2<sup>nd</sup> ed.). Chicago, IL. American Dietetic Association.
- Evans, W.J., Morley, J.E., Argiles, J., Bales, C., Baracos, V., Guttridge, D., Jatoi, A., Kalantar-Zadeh, K., Lochs, H., Mantovani, G., Marks, D., Mitch, W.E., Muscaritoli, M., Najand, A., Ponikowski, P., Fanelli, F. R.,

Schambelan, M., Schols, A., Schuster, M., Thomas, D., Wolfe, R., & Anker, S.D., (2008). Cachexia: A new definition. *Clinical Nutrition*, 27,793-799. doi:10.1016/j.clnu.2008.06.013.

Dewey, A., Baughan, C., Dean, T. P., Higgins, B., & Johnson, I. (2009). Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia. *The Cochrane Collaborative*. doi: 10.1002/14651858.CD004597.pub2.

Fearon, Kenneth C.H.; et al. Cancer cachexia; Influence of systemic ketosis on substrate levels and nitrogen metabolism. *The American Journal of Clinical Nutrition*, 1987; 47:42-48, American Society for Nutrition, Bethesda, MD.

Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes: A risk assessment model for establishing upper intake levels for nutrients. 1998, 2007, May 27; 82, National Academy Press, Washington, D.C. Available from <http://www.nap.edu/catalog/6432.html>

Fraser Health: Hospice Palliative Care Program Symptom Guidelines. (2006). Nutrition and Cachexia. Retrieved May 10, 2013 from: <http://www.fraserhealth.ca/media/15FHSymptomGuidelinesNutritionCachexia.pdf>

Good, P., Cavenagh J., Mather, M., & Ravenscroft, P. Medically assisted nutrition for palliative care patients (Protocol). *The Cochrane Library*, 2008, 1, John Wiley & Sons, Ltd., Hoboken, NJ.

Harada, M. et al. (2016). A Case of Possible Acute Refeeding Syndrome: A Review of a Rare, But Potentially Life- Threatening Diagnosis. Retrieved from <https://openventio.org/Volume2-Issue1/A-Case-of-Possible-Acute-Refeeding-Syndrome-A-Review-of-a-Rare-But-Potentially-Life-Threatening-Diagnosis-EMOJ-2-123.pdf>

Hart, S., Franklin, R. et al. (2013). A review of feeding methods used in treatment of anorexia nervosa. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4081821/>

Hemming, L., & Maher, F. Understanding cachexia and excessive weight loss in cancer. *British Journal of Community Nursing*, 2005; 10(11): 492-495, Mark Allen Publishing Ltd., Dinton Nr Salisbury Wiltshire, UK.

Huhmann, M. B., & August, D. A. Review of American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) clinical guidelines for nutrition support in cancer patients: nutrition screening and assessment. *Nutrition in Clinical Practice*, 2008; 23(2):182-188, American Society for Parenteral and Enteral Nutrition, Silver Spring, MD.

Jatoi, A. (2015). Anorexia and Cachexia. Retrieved from <https://pdfs.semanticscholar.org/3cd7/f28ad82d6c687be5ddb6c1af8c200469ceaa.pdf>

Jatoi, A. and Loprinzi, C. (2016). Pharmacologic management of cancer anorexia/ cachexia. Retrieved from <https://www.uptodate.com/contents/pharmacologic-management-of-cancer-anorexia-cachexia>

Jatoi, A. and Loprinzi, C. (2016). Pathogenesis, clinical features, and assessment of cancer cachexia. Retrieved from <https://www.uptodate.com/contents/pathogenesis-clinical-features-and-assessment-of-cancer-cachexia>

Jatoi, A. Fish oil, lean tissue, and cancer: is there a role for eicosapentaenoic acid in treating the cancer anorexia/weight loss syndrome? *Critical Reviews in Oncology Hematology*, 2005; 55:37-43, Elsevier Ireland Ltd., Shannon, Co. Clare.

Jatoi, A. Fatty acid supplements for cancer-associated weight loss. *Nutrition in Clinical Practice*, 2005; 20(4):394-399, American Society for Parenteral and Enteral Nutrition, Silver Spring, MD.

Jatoi, A. Is bortezomib, a proteasome inhibitor, effective in treating cancer-associated weight loss? Preliminary results from the North Central Cancer Treatment Group. *Supportive Care in Cancer*, 2005;13: 381-386, Springer, New York, NY.

Loprinzi, C. L., & Jatoi, A. (2013). Pharmacological management of cancer anorexia/cachexia. In: D.S. Barsow (Ed.). *UpToDate*. Waltham, MA: UpToDate. Retrieved January 10, 2013 from: [http://www.uptodate.com/contents/pharmacologic-management-of-cancer-anorexia-cachexia?source=search\\_result&search=Pharmacologic+management+of+cancer+anorexia%2Fcachexia&selectedTitle=1~16](http://www.uptodate.com/contents/pharmacologic-management-of-cancer-anorexia-cachexia?source=search_result&search=Pharmacologic+management+of+cancer+anorexia%2Fcachexia&selectedTitle=1~16)

Marian, M., & Roberts, S. (2010). *Clinical Nutrition for Oncology Patients*. Canada, Mississauga, ON. Jones and Bartlett Publishers.

Mattox, T.W. Treatment of unintentional weight loss in patients with cancer. *Nutrition in Clinical Practice*, 2005; 20(4):400-410, American Society for Parenteral and Enteral Nutrition, Silver Spring, MD.

Miller, S.J. Death resulting from overzealous total parenteral nutrition: The refeeding syndrome revisited. *Nutrition in Clinical Practice*, 2008; 23(2):166-171, American Society for Parenteral and Enteral Nutrition, Silver Spring, MD.

Molassiotis, A. Anorexia and weight loss in long-term survivors of haematological malignancies. *Journal of Clinical Nursing*, 2003; 12: 925-927, Blackwell Publishing Ltd., Oxford, England.

Morley, J.E. Anorexia of aging: physiologic and pathologic. *The American Journal of Clinical Nutrition*, 1997; 66:760-773, American Society for Nutrition, Bethesda, MD.

National Cancer Institute. Nutrition in Cancer Care. PDQ Health Professional Version. August 22 2008. [cited 2008, Sept 02] Available from: <http://www.cancer.gov/cancertopics/pdq/supportivecare/nutrition/healthprofessional>

National Collaborating Centre for Mental Health (UK). Eating Disorders: Core Interventions in the Treatment and Management of Anorexia Nervosa, Bulimia Nervosa and Related Eating Disorders. Leicester (UK): British Psychological Society (UK); 2004. (NICE Clinical Guidelines, No. 9.) 6, Treatment and management of anorexia nervosa. Retrieved from <https://www.ncbi.nlm.nih.gov/books/NBK49301/>

National Comprehensive Cancer Network, (2012). Palliative Care. Retrieved March 23, 2013 from: [http://www.nccn.org/professionals/physician\\_gls/pdf/palliative.pdf](http://www.nccn.org/professionals/physician_gls/pdf/palliative.pdf)

National Institute of Health & National Cancer Institute (2010). Common Terminology Criteria for Adverse Events. Available from: [http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE\\_4.03\\_2010-06-14\\_QuickReference\\_8.5x11.pdf](http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf)

Ottawa Hospital Research Institute and University of Ottawa, Canada. (2016). Appetite Loss Practice Guide. Retrieved from [https://ktcanada.ohri.ca/costars/Research/docs/COSTaRS\\_Pocket\\_Guide\\_March2016.pdf](https://ktcanada.ohri.ca/costars/Research/docs/COSTaRS_Pocket_Guide_March2016.pdf)

Palombine, J. (2006). Cancer-related weight loss. *Clinical Journal of Oncology Nursing*, 10(6), 831-832.

Preedy, V.R. (2011). *Diet and Nutrition in Palliative Care*. 6000 Broken Sound Parkway NW, Suite 300. Taylor and Francis Group.

Reymann, P. Anorexia. In Hickey M, Newton S, editors. Telephone Triage for Oncology Nurses. Pittsburgh, PA: Oncology Nursing Society; 2005. p.63-65.

Seres, D., Valcarcel, M., and Guillaume, A. (2012). Advantages of enteral nutrition over parenteral nutrition. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3589130/>

Valentine, K. A., & Hull, R.D. (2014). Therapeutic use of warfarin and other vitamin K antagonists. Retrieved September 29, 2014 from: <http://www.uptodate.com/contents/therapeutic-use-of-warfarin-and-other-vitamin-k-antagonists?source=machineLearning&search=warfarin&selectedTitle=5~150&sectionRank=1&anchor=H21#H21>

Whitman, M.M. (2000). The starving patient: Supportive care for people with cancer. *Clinical Journal of Oncology Nursing*, 4(3), 121-125.

Wilson, R.L. (2000). Optimizing nutrition for patients with cancer. *Clinical Journal of Oncology Nursing*, 4(1), 23-28.

## Constipation

Agra, Y., Sacristan, A., Gonzalez, M., Ferrari, M., Portugues, A., Calvo, M.J. (1998). Efficacy of senna versus lactulose in terminal cancer patients treated with opioids. *Journal of Pain & Symptom Management*, 15(1), 1-7.

American College of Gastroenterology Chronic Constipation Task Force. (2005). Evidence - based approach to the management of chronic constipation in North America. *American Journal of Gastroenterology*, 100(suppl 1), S1 – S21.

Avila, J.G. (2004). Pharmacologic treatment of constipation in cancer patients. *Cancer Control*, 11(3), S10-S18.

Bisanz, A., Woolery, M., Lyons, H.F., Gaido, L., Yenulevich, M.C., Fulton, S. Constipation. Putting Evidence into Practice. Pittsburgh, PA, Oncology Nursing Society. 2007: 1-6 [cited August 1, 2007]. Available from: [www.ons.org/outcomes](http://www.ons.org/outcomes)

Blessner, S.D. (2006). Practical symptom – based evaluation of chronic constipation. *The Journal of Family Practice*. 55(7), 580–584.

Canadian Association of Nurses in Oncology/ Association canadienne des infirmieres en oncologie (CANO/ACIO). Practice Standards and Competencies for the Specialized Oncology Nurse. 2006:1-47.

Cancer Care Ontario. (2012). Symptom management guide- to- practice: Bowel care. Retrieved from: [https://www.cancercare.on.ca/CCO\\_DrugFormulary/Pages/FileContent.aspx?fileId=154791](https://www.cancercare.on.ca/CCO_DrugFormulary/Pages/FileContent.aspx?fileId=154791)

Cancer Care Ontario, Nursing Professional Advisory Committee. Constipation guideline. Telephone Nursing Practice and Symptom Management Guidelines. 2004, Apr 5 [cited 2007 July 14]:13-14. Available from: <http://www.cancercare.on.ca/documents/NursingTelephonePracticeGuidelines.pdf>

Carter, B., Black, F., Downing, G.M. Bowel Care – Constipation and diarrhea. In: Downing GM, Wainwright W, editors. Medical Care of the Dying. Victoria, B.C. Canada: Victoria Hospice Learning Society for Palliative Care; 2006. p. 341-362.

Choi, Y.S., Billings, A. (2002). Opioid antagonists: A review of their role in palliative care, focusing on use in opioid related constipation. *Journal of Pain & Symptom Management*, 24(1), 71–90.

Cope, D.G. (2001). Management of chemotherapy – induced diarrhea and constipation. *Nursing Clinics of North America*. 36(4), 695–707.

Daeninck, P., & Crawford, G. Constipation. I: MacDonald N, Oneshcuk D, Hagen N, Doyle D, editors. Palliative Medicine – A Case Based Manual (2<sup>nd</sup> ed.). New York: Oxford University Press Inc.; 2005. p. 201–211.

Davis M., Gamier P. New Options in Constipation Management. *Curr.Oncol.Rep.* 2015;17(12) (pagination):Arte Number: 55. ate of Pubaton: 01 e 2015.

Dean, M., Harris, J.D., Regnard, C., & Hockley, J. Constipation. *Symptom Relief in Palliative Care.* Oxford, United Kingdom: Radcliffe Publishing; 2006. p 75–79.

Drost, J., & Harris, L.A. (2006). Diagnosis and management of chronic constipation. *Journal of the American Academy of Physician Assistants*, 19(11), 24–28.

Erichsen E, Milberg A, Jaarsma T, Friedrichsen M. Constipation in specialized palliative care: factors related to constipation when applying different definitions. *Support.Care Cancer* 2016 Feb;24(2):691-698.

Erie St, C. Constipation guidelines. *Palliative Care Management Tool.* 3<sup>rd</sup> ed. 2007, January. Version 3.1:7 - 8. Available from: [http://www.ccac-ont.ca/Upload/esc/General/Palliative\\_Care\\_Management\\_Tool\\_v3\\_1.pdf](http://www.ccac-ont.ca/Upload/esc/General/Palliative_Care_Management_Tool_v3_1.pdf)

Folden, S.L., Backer, J.H., Maynard, F., Stevens, K., Gilbride, J.A., Pires, M., & Jones, K. Practice guidelines for the management of constipation in adults. *Rehabilitation Nursing Foundation.* 2002 [cited 2007, July 14]:1 – 51. Available from: [www.rehabnurse.org](http://www.rehabnurse.org)

Fraser Health: Hospice Palliative Care Program Symptom Guidelines (2006). Bowel care. Retrieved from: <http://www.fraserhealth.ca/NR/rdonlyres/e2vvr7bsr65rjaa2qu4nkjnsbhqlv3s2ahqffpomn3mye7zvxjzrh4ua3dutlgez67sj5gb2ipl2i/04FHSymptomGuidelinesBowelCare.pdf>

Gervais C., Ducrotte P., Piche T., Di Palma M., Jovenin N., Scotte F. Constipation and cancer: Current strategies. *Bull.Cancer* 2016 01 Sep 2016;103(9):794-804.

Gibson, R.J., & Keefe, D.M.K. (2006). Cancer chemotherapy – induced diarrhoea and constipation: Mechanisma of damage and prevention strategies. *Supportive Care Cancer*, 14(9), 890–900.

Hawley, P. H., & Byeon, J.J. (2008). A comparison of sennosides-based bowel protocols with and without Docusate in hospitalised patients with cancer. *Journal of Palliative Medicine*, 11, 575-581. .

Heitkemper, M., & Wolfe, J. (2007). Challenges in chronic constipation. *The Nurse Practitioner.* 32(4), 36–42.

Hurdon, V., Viola, R., & Schroder, C. (2000). How useful is Docusate in patients at risk for constipation? A systematic review of the evidence in the chronically ill. *Journal of Pain & Symptom Management*,19(2),130–136.

Klaschik, E., Nauck F, Ostgathe. (2003). Constipation – modern laxative therapy. *Supportive Care Cancer*, 11, 679– 685.

Lawrence, L. S., Bouvette, M., Angelis, C. D., & Pereira, J. L. (2010). Consensus recommendations for the management of constipation in patients with advanced, progressive illness. *Journal of Pain and Symptom Management*, 40(5), 761-773.

Massey, R.L., Haylock, P.J., & Curtiss, C. Constipation. In: Yarbro CH, Frogge MH, Goodman M, editors. *Cancer Symptom Management.* 3<sup>rd</sup> ed. Sudbury, Massachusetts: Jones and Bartlett Publishers; 2004. p.512–527.

McMillan, S.C. (2004). Assessing and managing opiate- induced constipation in adults with cancer. *Cancer Control*, 11(3), S3–S9.

McQuade R.M., Stojanovska V., Abalo R., Bornstein J.C., Nurgali K. Chemotherapy-induced constipation and diarrhea: Pathophysiology, current and emerging treatments. *Frontiers in Pharmacology* 2016;7(NOV) (pagination):Arte Number: 414. ate of Pubaton: 03 No 2016.

National Cancer Institute. Gastrointestinal Complications. PDQ Health Professional Version. 2012. Available from: <http://www.cancer.gov/cancertopics/pdq/supportivecare/gastrointestinalcomplications/HealthProfessional>

National Institute of Health & National Cancer Institute (2010). Common Terminology Criteria for Adverse Events. Available from : [http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE\\_4.03\\_2010-06-14\\_QuickReference\\_8.5x11.pdf](http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf)

National Oncology Alliance. Constipation. NOA Treatment Guidelines. 2006. Available from: [http://guidelines.noainc.com/documents/Guidelines/Constipation\\_Guideline.pdf](http://guidelines.noainc.com/documents/Guidelines/Constipation_Guideline.pdf)

Pallentino, J., Schiller, L.R., & White, K.M. (2006). Chronic constipation: New thoughts about an old problem. *John Hopkins Advanced Studies in Nursing*, 4(8), 209–218.

Practice Evidenced-based in Nutrition (PEN). (2013). Healthy Lifestyle: Key Practice Points. Retrieved from: <http://www.pennutrition.com/KnowledgePathway.aspx?kpid=3127&pqcatid=144&pqid=14591>

Registered Nurses Association of Ontario. Prevention of constipation in the older adult population. Nursing Best Practice Guidelines. 2005 March; [cited 2007, July 20]:1–59. Available from: [http://www.rnao.org/Storage/11/610\\_BPG\\_Prevent\\_Constipation\\_rev05.pdf](http://www.rnao.org/Storage/11/610_BPG_Prevent_Constipation_rev05.pdf)

Solomon, R., & Cherny, N.I. (2006). Constipation and diarrhea in patients with cancer. *The Cancer Journal*, 12(5), 355-364.

Sykes, N.P. (2006). The pathogenesis of constipation. *The Journal of Supportive Oncology*, 4(5), 213–218.

Tamayo, A.C., & Diaz- Zuluaga, P.A. (2004). Management of opioid – induced bowel dysfunction in cancer patients. *Supportive Care Cancer*, 12, 613–618.

Wirz, S., & Klashkik, E. (2005). Management of constipation in palliative care patients undergoing opioid therapy: is polyethylene glycol an option? *American Journal of Hospice and Palliative Medicine*, 22(5), 375–381.

Woolery, M., Bisanz, A., Lyons, H., Gaido, L., Yenulevich, M., Fulton, S. & McMillan, S. (2008). Evidence based interventions for the prevention and management of constipation in patients with cancer. *Prevention and Management of Constipation*, 12(2), 317-337.

Yuan, C.S., Wei, G., Foss, J.F., O'Connor, M., Karrison, T., & Osinski, J. (2002). Effects of subcutaneous methyl naltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. *The Journal of Pharmacology and Experimental Therapeutics*, 300(1):118-23.

## Diarrhea (Cancer-Related)

Amerine, E., & Keirse, M. (2006). Managing acute diarrhea. *Nursing*. 36(9),1-4.

Andreyev, J., Dr, Ross, P., FRCP, Donnellan, C., MRCP, Lennan, E., RGN, Leonard, P., FRCP, Waters, C., BSc, . . . Ferry, D., Prof. (2014). Guidance on the management of diarrhoea during cancer chemotherapy. *Lancet Oncology*, 15(10), e447-e460. doi:10.1016/S1470-2045(14)70006-3

Benson, A.B., Ajani, J.A., Catalano, R.B., Engelking, C., Kornblau, S.M., & Martenson, J.A., et al. (2004) Recommended guidelines for the treatment of cancer treatment–induced diarrhea. *Journal of Clinical Oncology*. 22(14): 2918–2926.

Bush, N.J. (2004). Chemotherapy–induced diarrhea. *Oncology Nursing Forum*, 31(5), 889-892.



Canadian Association of Nurses in Oncology/ Association canadienne des infirmières en oncologie (CANO/ACIO). Practice Standards and Competencies for the Specialized Oncology Nurse. 2006:1-47.

Cancer Care Ontario. (2012). Algorithm: Diarrhea Symptoms in Adults with Cancer. Available from: <https://www.cancercareontario.ca/en/symptom-management/3151>

Cancer Care Ontario, Nursing Professional Advisory Committee. Diarrhea guideline. Telephone Nursing Practice and Symptom Management Guidelines. 2004, Apr 5 [cited 2007 Feb 14]:13-14. Available from: <http://www.cancercare.on.ca/documents/NursingTelephonePracticeGuidelines.pdf>

Cancer Care Ontario. (2012). Symptom Management Guide-to-Practice: Bowel Care. Available from: <https://www.cancercareontario.ca/en/symptom-management/3151>

Cope, D.G. (2001). Management of chemotherapy – induced diarrhea and constipation. *Nursing Clinics of North America*. 2001, 36(4), 695–707.

Dieticians of Canada. (2012). Lactose Intolerance Background. Available from: <https://www.dietitians.ca/Your-Health/Nutrition-A-Z/Lactose.aspx>

Dieticians of Canada. (2015). Managing Diarrhea. Available from: <http://adultmetabolicdiseasesclinic.ca/resources/Managing-Diarrhea.pdf>

Dranitsaris, G., Maroun, J., & Shah, A. (2005). Estimating the cost of illness in colorectal cancer patients who were hospitalized for severe chemotherapy–induced diarrhea. *Canadian Journal of Gastroenterology*, 19(2), 83–87.

e-CPS [Internet]. Ottawa (ON): Canadian Pharmacists Association; c2014 . Available from: <http://www.e-cps.ca>.

Engelking, C. Diarrhea. In: Yarbro CH, Frogge MH, Goodman M, editors. Cancer Symptom Management. 3rd ed. Sudbury, Massachusetts: Jones and Bartlett Publishers; 2004. p. 528-557.

Fraser Health: Hospice Palliative Care Program Symptom Guidelines (2006). Bowel care. Retrieved from: <http://www.fraserhealth.ca/NR/rdonlyres/e2vvr7bsr65rjaa2gu4nkjnsbhqlv3s2ahqffpomn3mye7zvxjzrh4ua3dudtlgezx67s5qb2ipl2i/04FHSymptomGuidelinesBowelCare.pdf>

Gibson, R. J., Keefe, D. M., Lalla, R. V., Bateman, E., Blijlevens, N. M., Fijlstra, M., . . . For The Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). (2013). Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. *Supportive Care in Cancer*, 21(1), 313-326. doi:10.1007/s00520-012-1644-z

Goldberg, A. R. J., Gabrail, N., Raut, M., Kim, R., Sung, C.Y.S., & Yonglong Zhou, M.S. (2005). Clinical implications of chemotherapy–induced diarrhea in patients with cancer. *The Journal of Supportive Oncology*, 3(3), 227-232.

Grenon, N. N., & Chan, J. (2009). Managing toxicities associated with colorectal cancer chemotherapy and targeted therapy: A new guide for nurses. *Clinical Journal of Oncology Nursing*, 13(3), 285-296. doi:10.1188/09.CJON.285-296

Gwede, C.K. (2003). Overview of radiation- and chemoradiation–induced diarrhea. *Seminars in Oncology Nursing*, 19(4 Suppl 3), S6-S10.

Hogan, C.M. (1998). The nurse's role in diarrhea management. *Oncology Nurses Forum*, 25(5), 879–886.

Hovan, A. (2014). Update on the management of oral mucositis. *Journal of Family Practice in Oncology*. 22(3). Available from: [http://www.bccancer.bc.ca/family-oncology-network-site/Documents/2014SpringFPONjournal\\_webApr8.pdf](http://www.bccancer.bc.ca/family-oncology-network-site/Documents/2014SpringFPONjournal_webApr8.pdf)

- Kornblau, S., Benson, A.B., Catalano, R.B., Champlin, R.E., Engelking, C., Field, M., et al. (2000). Management of cancer treatment–related diarrhea: Issues and therapeutic strategies. *Journal of Pain and Symptom Management*, 19(2), 118–129.
- Krishnamurthi, S. S. (2013). Enterotoxicity of chemotherapeutic agents. Retrieved from: [http://www.uptodate.com/contents/enterotoxicity-of-chemotherapeutic-agents?source=search\\_result&search=enterotoxicity+of+chemotherapy+agents&selectedTitle=1%7E150](http://www.uptodate.com/contents/enterotoxicity-of-chemotherapeutic-agents?source=search_result&search=enterotoxicity+of+chemotherapy+agents&selectedTitle=1%7E150)
- Lalla, R. V., Bowen, J., Barasch, A., Elting, L., Epstein, J., Keefe, D. M., . . . The Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO). (2014). MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy: MASCC/ISOO mucositis guidelines. *Cancer*, 120(10), 1453-1461. doi:10.1002/cncr.28592
- Mcquade, R. M., & Bornstein, J. C. (2016). chemotherapy-induced constipation and diarrhoea: Pathophysiology, current and emerging treatments. *Frontiers in Pharmacology*, doi:10.3389/fphar.2016.00414
- Muehlbauer, P. M., Thorpe, D., Davis, A., Drabot, R., Rawlings, B. L., & Kiker, E. (2009). Putting evidence into practice: Evidence- based interventions to prevent, manage, and treat chemotherapy-and radiotherapy-induced diarrhea. *Clinical Journal of Oncology Nursing*, 13 (3), 336-341.
- National Cancer Institute. Gastrointestinal Complications. PDQ Health Professional Version. 2012. Retrieved from: <http://www.cancer.gov/cancertopics/pdq/supportivecare/gastrointestinalcomplications/HealthProfessional>
- National Institute of Health & National Cancer Institute (2010). Common Terminology Criteria for Adverse Events. Available from : [http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE\\_4.03\\_2010-06-14\\_QuickReference\\_8.5x11.pdf](http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf)
- O'Brien, B.E., Kaklamani, V.G., & Benson, A.B. (2005). The assessment and management of cancer treatment–related diarrhea. *Clinical Colorectal Cancer*, 4(6), 375-381.
- Pessi, M. A., Zilembo, N., Haspinger, E. R., Molino, L., Di Cosimo, S., Garassino, M., & Ripamonti, C. I. (2013;2014;). Targeted therapy-induced diarrhea: A review of the literature. *Critical Reviews in Oncology and Hematology*, 90(2), 165-179. doi:10.1016/j.critrevonc.2013.11.008
- Rutledge, D.N., & Engelking, C. (1998). Cancer-related diarrhea: Selected findings of a national survey of oncology nurse experiences. *Oncology Nurses Forum*, 25(5), 861–872.
- Saltz, L.B. (2003). Understanding and managing chemotherapy–induced diarrhea. *The Journal of Supportive Oncology*. 1(1), 35–46.
- Schiller, L. (2006). Nutrition management of chronic diarrhea and malabsorption. *Nutrition in Clinical Practice*, 21(1), 34–39.
- Shaw, C., & Taylor, L. (2012). Treatment-related diarrhea in patients with cancer. *Clinical Journal of Oncology Nursing*, 16(4), 413-417.
- Solomon, R., & Cherny, N.I. (2006). Constipation and diarrhea in patients with cancer. *The Cancer Journal*, 12(5), 355-364.
- Stein, A., Voigt, W., & Jordan, K. (2010). Chemotherapy-induced diarrhea: Pathophysiology, frequency and guideline based management. *Therapeutic Advances in Medical Oncology*, 2(2), 51-63.
- Stern, J., & Ippoliti, C. (2003). Management of acute cancer treatment–induced diarrhea. *Seminars in Oncology Nursing*, 19 (4 Suppl 3), S11-S16.

Tarricone, R., Abu Koush, D., Nyanzi-Wakholi, B., & Medina-Lara, A. (2016). A systematic literature review of the economic implications of chemotherapy-induced diarrhea and its impact on quality of life. *Critical Reviews in Oncology and Hematology*, 99, 37-48. doi:10.1016/j.critrevonc.2015.12.012

Valentine, K. A., & Hull, R.D. (2014). Therapeutic use of warfarin and other vitamin K antagonists. Retrieved September 29, 2014 from: <http://www.uptodate.com/contents/therapeutic-use-of-warfarin-and-other-vitamin-k-antagonists?source=machineLearning&search=warfarin&selectedTitle=5~150&sectionRank=1&anchor=H21#H21>

Viale, H.P., Fung, A., & Zitella, L. (2005). Advanced colorectal cancer: Current treatment and nursing management with economic considerations. *Clinical Journal of Oncology Nursing*, 9(5), 541-552.

Viale, H.P., & Sommers, R. (2007). Nursing care of patients receiving chemotherapy for metastatic colorectal cancer: Implications of the treatment continuum concept. *Seminars in Oncology Nursing*, 23(1), 22 -35.

Viele, C.S. (2003). Overview of chemotherapy – induced diarrhea. *Seminars in Oncology Nursing*, 19(4 Suppl 3), S2-S5.

Wadler, S., Benson, A.B., Engelking, C., Catalano, R., Field, M., Kornblau, S.M., et al. (1998). Recommended guidelines for the treatment of chemotherapy–induced diarrhea. *Journal of Clinical Oncology*, 16(9), 3169-3178.

## Dyspnea / Breathlessness

American Thoracic Society. (1999). Dyspnea. Mechanisms, assessment and management: A consensus statement of the American Thoracic Society. *American Journal of Respiratory Critical Care Medicine*, 159(1), 321-340.

Ahmed, A., Graber, M. (2017). Evaluation of the adult with dyspnea in the emergency department. *UpToDate*®. Retrieved 11/10/17 from: [https://www.uptodate.com/contents/evaluation-of-the-adult-with-dyspnea-in-the-emergency-department?source=search\\_result&search=Dyspnea&selectedTitle=2~150](https://www.uptodate.com/contents/evaluation-of-the-adult-with-dyspnea-in-the-emergency-department?source=search_result&search=Dyspnea&selectedTitle=2~150)

Bailey, P., Boyles, C., Cloutier, J., Bartlett, A., Goodridge, D., Manji, M., & Dusek, B. (2013). Best practice in nursing care of dyspnea: The 6th vital sign in individuals with COPD. *Journal of Nursing Education and Practice*, 3(1),108-122.

Baldwin J., & Cox, J. (2016). Treating dyspnea: Is oxygen therapy the best option for all patients?. *Medical Clinics of North America*, 100(5), 1123-1130. doi: <http://dx.doi.org/10.1016/j.mcna.2016.04.018>

Barbera A.R., & Jones, M. P. (2016). Dyspnea in the elderly. *Emergency Medicine Clinics of North America*, 34(3), 543-558. doi: <http://dx.doi.org/10.1016/j.emc.2016.04.007>

Bailey, P., Boyles, C., Cloutier, J., Bartlett, A., Goodridge, D., Manji, M., & Dusek, B. (2013). Best practice in nursing care of dyspnea: The 6th vital sign in individuals with COPD. *Journal of Nursing Education and Practice*, 3(1),108-122.

Bausewein, C., & Simon, S. T. (2013). Shortness of breath and cough in patients in palliative care. *Deutsches Arzteblatt International*, 110(33-34), 563-571. doi: <https://dx.doi.org/10.3238/arztebl.2013.0563>

BC Guidelines (2017). Palliative Care for the Patient with Incurable Cancer or Advanced Disease. Part 2: Pain and Symptom Management – Dyspnea. *BC Palliative Care Guidelines*. Retrieved 11/10/17 from : <http://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/bc-guidelines/palliative-pain-management#part2-dyspnea>

BC Palliative Care Guidelines. Palliative Care for the Patient with Incurable Cancer or Advanced Disease. Guidelines and Protocols Advisory Committee. December 30, 2011. Retrieved 10/17/17 from: [http://www.bcguidelines.ca/submenu\\_palliative.html](http://www.bcguidelines.ca/submenu_palliative.html)

BenAharon I., GaftarGvili A., Leibovici L., & Stemmer, S. M. (2012). Interventions for alleviating cancer-related dyspnea: A systematic review and meta-analysis. *Acta Oncologica*, 51(8), 996-1008. doi: <http://dx.doi.org/10.3109/0284186X.2012.709638>

Canadian Association of Nurses in Oncology/ Association canadienne des infirmieres en oncologie (CANO/ACIO). Practice Standards and Competencies for the Specialized Oncology Nurse. 2006:1-47.

Cancer Care Ontario, Nursing Professional Advisory Committee. Breathlessness. Telephone Nursing Practice and Symptom Management Guidelines. 2004, Apr 5 [cited September 17, 2007] 17–18. Available from: <http://www.cancercare.on.ca/documents/NursingTelephonePracticeGuidelines.pdf>

CabazonGutierrez L., KhosraviShahi P., CustodioCabello S., MunizGonzalez F., CanoAguirre M.P., & AlonsoViteri, S. (2016). Opioids for management of episodic breathlessness or dyspnea in patients with advanced disease. *Supportive Care in Cancer*, 24(9), 4045-4055. doi: <http://dx.doi.org/10.1007/s00520-016-3316-x>

Cancer Care Ontario. (2010). Symptom management guide to practice: Dyspnea. Retrieved June 19, 2013 from: [https://www.cancercare.on.ca/CCO\\_DrugFormulary/Pages/FileContent.aspx?fileID=97469](https://www.cancercare.on.ca/CCO_DrugFormulary/Pages/FileContent.aspx?fileID=97469)

Chin C., & Booth, S. (2016). Managing breathlessness: A palliative care approach. *Postgraduate Medical Journal*, 92(1089), 393-400. doi: <http://dx.doi.org/10.1136/postgradmedj-2015-133578>

Clemens K.E., Faust M., & Bruera, E. (2012). Update on combined modalities for the management of breathlessness. *Current Opinion in Supportive and Palliative Care*, 6(2), 163-167. doi: <http://dx.doi.org/10.1097/SPC.0b013e3283530fee>

COSTaRS Team (2016). Breathlessness/Dyspnea. *Remote Symptom Practice Guides for Adults on Cancer Treatments*, 11-12. Retrieved 11/10/17 from: [https://ktcanada.ohri.ca/costars/COSTaRS\\_Practice\\_Guides\\_ENGLISH\\_March2016.pdf](https://ktcanada.ohri.ca/costars/COSTaRS_Practice_Guides_ENGLISH_March2016.pdf)

Disalvo, W.M., Joyce, M.M., Culkin, A.E., Tyson, L.B., & Mackay, K. (2007). Dyspnea. Putting Evidence into Practice. Pittsburgh PA, Oncology Nursing Society. *Clinical Journal of Oncology Nursing*, 12(2), 1-4.

Donesky, D. (2015). Management of acute breathlessness in the person with chronic refractory breathlessness. *Current Opinion in Supportive & Palliative Care*, 9(3), 212-216. doi: <https://dx.doi.org/10.1097/SPC.0000000000000153>

Dudgeon, D., Shad, J. (2017). Assessment and management of dyspnea in palliative care. *UpToDate*® Retrieved 11/10/17 from: [https://www.uptodate.com/contents/assessment-and-management-of-dyspnea-in-palliative-care?source=search\\_result&search=Dyspnea&selectedTitle=3~150](https://www.uptodate.com/contents/assessment-and-management-of-dyspnea-in-palliative-care?source=search_result&search=Dyspnea&selectedTitle=3~150)

Fraser Health: Hospice Palliative Care Program Symptom Guidelines (2009). Dyspnea. Retrieved from: <http://www.fraserhealth.ca/media/Dyspnea.pdf>

Ganley, B.J., & Rosario, D.I. (2013). The smoking attitudes, knowledge, intent, and behaviors of adolescents and young adults: Implications for nursing practice. *Journal of Nursing Education and Practice*. 3(1), 40-50

Gok Metin Z., & Arikan Donmez, A. (2016). Dyspnea management in patients with cancer. *Turk Onkoloji Dergisi*, 31(2), 61-67. doi: <http://dx.doi.org/10.5505/tjo.2016.1366>

- Gomutbutra P., O'Riordan D.L., & Pantilat, S. Z. (2013). Management of moderate-to-severe dyspnea in hospitalized patients receiving palliative care. *Journal of Pain and Symptom Management*, 45(5), 885-891. doi: <http://dx.doi.org/10.1016/j.jpainsymman.2012.05.004>
- Hayen A., Herigstad M., & Pattinson, K. T. S. (2013). Understanding dyspnea as a complex individual experience. *Maturitas*, 76(1), 45-50. doi: <http://dx.doi.org/10.1016/j.maturitas.2013.06.005>
- Hood, L. E., Harwood, K.V. Dyspnea In: Yarbro CH, Frogge MH, Goodman M, editors. *Cancer Symptom Management*. 3<sup>rd</sup> ed. Sudbury, Massachusetts: Jones and Bartlett Publishers; 2004. p. 29–46.
- Houlihan, N.G., Inzeo, D., Joyce, M., & Tyson, L.B. (2004). Symptom management in lung cancer. *Clinical Journal of Oncology Nursing*, 8(6), 645–652.
- Inzeo, D., & Tyson, L. (2003). Nursing assessment and management of dyspneic patients with lung cancer. *Clinical Journal of Oncology Nursing*, 7(3), 332-333.
- Jantarakupt, P., & Porock, D. (2005). Dyspnea management in lung cancer: Applying evidence from chronic obstructive pulmonary disease. *Oncology Nursing Forum*. 32(4), 785–795.
- Joyce, M., McSweeney M., Carrieri-Kohlman, V.L., & Hawkins, J. (2004). The use of nebulized opioids in the management of dyspnea: Evidence synthesis. *Oncology Nursing Forum*, 31(3), 551–559.
- Janssen, D. J. A., Wouters, E. F. M., & Spruit, M. A. (2015). Psychosocial consequences of living with breathlessness due to advanced disease. *Current Opinion in Supportive & Palliative Care*, 9(3), 232-237. doi: <https://dx.doi.org/10.1097/SPC.000000000000146>
- Lok, C. W. (2016). Management of breathlessness in patients with advanced cancer: A narrative review. *American Journal of Hospice & Palliative Medicine*, 33(3), 286-290. doi:<https://dx.doi.org/10.1177/1049909114554796>
- Lynch, M.P. (2006). Dyspnea. *Clinical Journal of Oncology Nursing*, 10(3), 323–326.
- McCannon J., & Temel, J. (2012). Comprehensive management of respiratory symptoms in patients with advanced lung cancer. *Journal of Supportive Oncology*, 10(1), 1-8. doi: <http://dx.doi.org/10.1016/j.suponc.2011.07.002>
- Mercadante, S., Villari, P., & Ferrera, P. (2011). Refractory death rattle: deep aspiration facilitates the effects of antisecretory agents. *Journal of Pain and Symptom management*. 41(3). 637-630. doi: 10.1016/j.jpainsymman.2010.06.012
- National Institute of Health & National Cancer Institute (2010). Common Terminology Criteria for Adverse Events. Available from : [http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE\\_4.03\\_2010-06-14\\_QuickReference\\_8.5x11.pdf](http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf)
- Oncology Nursing Society. Dyspnea, definitions list. Evidence – Based Practice Resource Area. [cited September 17, 2007]. Available from: <http://onsopcontent.ons.org/toolkits/evidence/Clinical/summaries.html>
- Oncology Nursing Society. Dyspnea, Evidenced – based summaries. Evidence – Based Practice Resource Area. [cited September 17, 2007]. Available from: <http://onsopcontent.ons.org/toolkits/evidence/Clinical/summaries.html>
- Qaseem, A., Snow, V., Shekelle, P., Casye, D., Cross, T., & Owens, D. (2008). Palliative Care of Pain, Dyspnea, and Depression at the End of Life: A Clinical Practice Guideline from the American College of Physicians. *Annals of Internal Medicine*. 148(2), 141-147.

Registered Nurses' Association of Ontario. Nursing care of dyspnea: The 6<sup>th</sup> vital sign in individuals with chronic obstructive pulmonary disease (COPD). Nursing Best Practice Guidelines. 2005, March: pp, 1–139. [cited October 3, 2007]. Available from: [http://www.rnao.org/Storage/11/604\\_BPG\\_COPD.pdf](http://www.rnao.org/Storage/11/604_BPG_COPD.pdf)

Sarna, L., & Bush, N.J. (2004). Symptom Management for the patient with lung cancer. Oncology Nursing Today Lesson Guide. 2004. Stratos Institute for Healthcare Performance, Inc. pp 1-18.

Swen, J.J., Nijenhuis, M., deBoer, A., Grandia, L., Maitland-van der Zee, A.H., Mulder, H., Rongen, G. A.P.J.M., van Schaik, R.H.N., Schalekamp, T., Touw, D.J., van der Wiede, J., Wilfert, B., Deneer, V.H.M., & Guchelaar, H.J. (2011). Pharmacogenetics: From bench to byte-An update of Guidelines. *Clinical pharmacology and Therapeutics*. 89(5), 662-673.

Schwartzstein, R. (2017). Approach to the patient with dyspnea. *UpToDate*©. Retrieved 11/10/17 from: [https://www.uptodate.com/contents/approach-to-the-patient-with-dyspnea?source=search\\_result&search=Dyspnea&selectedTitle=1~150](https://www.uptodate.com/contents/approach-to-the-patient-with-dyspnea?source=search_result&search=Dyspnea&selectedTitle=1~150)

Schwartzstein, R. (2017). Physiology of dyspnea. *UpToDate*©. Retrieved 11/10/17 from: [https://www.uptodate.com/contents/physiology-of-dyspnea?source=search\\_result&search=Dyspnea&selectedTitle=4~150](https://www.uptodate.com/contents/physiology-of-dyspnea?source=search_result&search=Dyspnea&selectedTitle=4~150)

The Lung Association. Breathe easy – Management of COPD: Coping strategies, S.O.S. FOR S.O.B. The Lung Association. 2005. [cited October 3, 2007] Available from: <http://www.lung.ca/copd/managment/coping/sos.html>

Thomas, J.R., von Gunten, C.F. (2003). Management of dyspnea. *The Journal of Supportive Oncology*, 1(1), 23–34.

Viola, R., Kiteley, C., Lloyd, N., Mackay, J.A., Wilson, J., & Wong, R. The Management of dyspnea in cancer patients: A clinical practice guideline. Program in Evidence – Based Care, Cancer Care Ontario. 2005, November 6: Evidence – Based Series #13 – 5: Section 1:1 – 4. [cited October 18, 2007]. Available from: <http://www.cancercare.on.ca/>

Williams, C.M. (2006). Dyspnea. *The Cancer Journal*, 12(5), 365–373.

## Fatigue

Bruera, E. Palliative Care: Overview of fatigue, weakness and asthenia.

*Up to Date* Retrieved August 4, 2017 from: <https://www.uptodate.com/contents/palliative-care-overview-of-fatigue-weakness-and-asthenia>

BC Centre for Palliative Care. BC Inter-Professional Palliative Symptom Management Guidelines (2017) <https://www.bc-cpc.ca/cpc/wp-content/uploads/2018/06/03.-SMG-Clinical-Best-Practices-print-col-fatigue-2018.pdf>

Cancer Care Ontario. How to Manage Your Fatigue. A Patient Guide (2017) Available from: <https://archive.cancercare.on.ca/common/pages/UserFile.aspx?fileID=357461>

Cancer Care Ontario. Nursing Professional Advisory Committee. Fatigue Guideline. Telephone Nursing Practice and Symptom Management Guidelines. 2004. Apr. 5 [cited 2007 August 16]: 17. Available from: <http://www.cancercare.on.ca/documents/NursingTelephonePracticeGuidelines.pdf>

Canadian Association of Nurses in Oncology/ Association canadienne des infirmières en Oncology (CANO/ACIO). Practice Standards and Competencies for the Specialized Oncology Nurse. 2006: 1-47.

Canadian Association of Psychosocial Oncology & Canadian Partnership Against Cancer. A Pan-Canadian Practice Guideline for Screening, Assessment and Management of Cancer-Related Fatigue in Adults, Version (2015). Available from: [https://www.capo.ca/pdf/CRF\\_Guideline.pdf](https://www.capo.ca/pdf/CRF_Guideline.pdf)

Campos, M. P. O., Hassan, B. J., Riechelmann, R., & Del Giglio, A. (2011). Cancer-related fatigue: A practical review. *Annals of Oncology*, 22, 1273-1279.

Cramp, F., & James, D. (2010). Exercise for the management of cancer-related fatigue in adults. *Cochrane Database of Systematic Reviews*, 11.

Escalante, C.P. Cancer-related fatigue: Treatment *Up to Date*. Retrieved August 4, 2017 from: <https://www.uptodate.com/contents/cancer-related-fatigue-treatment>

Escalante, C. P., & Manzullo, E. F. (2009). Cancer-related fatigue: The approach and treatment. *Journal of General Internal Medicine*, 24(suppl 2), 412-416.

Fourbert J. (2006). Cancer-related anemia and fatigue: Assessment and treatment. *Nursing Standard*. 20(36), 50-57.

Fraser Health Hospice Palliative Care Program. Fatigue. Hospice Palliative Care Program Symptom Guidelines. 2006, Dec 5; [cited 2007, August]: Available from: <http://www.fraserhealth.ca/NR/rdonlyres/embys6sfngqxxkuzrolqqephv2d35whl3vafxhnrnqqud2ofrrkkvfh74syoo2ovupn2bal043ayegp/11FHSymptomGuidelinesFatigue.pdf/>

Johnson, R. L., & Matzo, M. (2012). Cancer-related fatigue: Evidence-based recommendations for management. *American Journal of Nursing*, 112(4), 57-60.

Madden, J., & Newton, S. (2006). Why am I so tired all the time? Understanding cancer-related fatigue. *Clinical Journal of Oncology Nursing*, 10(5), 659-661.

Minton, O., Richardson, A., Sharpe, M., Hotopf, M., & Stone, P. (2010). Drug therapy for the management of cancer-related fatigue. *Cochrane Database of Systematic Reviews*, 7.

Mitchell, S.A. et al. (2014) Putting evidence into Practice: an Update of Evidence-Based Interventions for Cancer-Related Fatigue during and Following Treatment. *Clinical Journal of Oncology Nursing*. 18(6): pp.38-46

Mitchell, S., Beck, S., Hood, L., Moore, K., & Tanner, E. (2007). Putting evidence into practice: Evidence based interventions for fatigue during and following cancer and its treatment. *Clinical Journal of Oncology Nursing*, 11(1), 99-113.

Mitchell, S.A. et al. (2014) Putting Evidence into Practice: an Update of Evidence-Based Interventions for Cancer-Related Fatigue during and Following Treatment. *Clinical Journal of Oncology Nursing*. 18 (6): pp.38-46

Mitchell, S., & Berger, A. (2006). Cancer-related fatigue: The evidence base for assessment and management. Palliative and Supportive Care. *The Cancer Journal*, 12(5), 374-387.

Mustian, K.M. et al. (2017) Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue : A Meta-Analysis. *JAMA Oncology*. July 2017 3(7)pp.961-968

Nail, L.M. Fatigue. In: Yarbro CH, Frogge MH, Goodman M, editors. *Cancer Symptom Management*. 3rd ed. Sudbury, Massachusetts: Jones and Bartlett Publishers; 2004. p. 47-60.

National Cancer Institute. Fatigue PDQ Health Professional Version. August 2012. Available from: <http://www.cancer.gov/cancertopics/pdq/supportivecare/fatigue/HealthProfessional>

National Cancer Institute. Changes to Fatigue PDQ Summary (2017) Available from: [https://www.cancer.gov/about-cancer/treatment/side-effects/fatigue/fatigue-hp-pdq#link/277\\_toc](https://www.cancer.gov/about-cancer/treatment/side-effects/fatigue/fatigue-hp-pdq#link/277_toc)

National Comprehensive Cancer Network. Cancer-Related Fatigue. Version 2. (2018). Available from: [http://www.nccn.org/professionals/physician\\_gls/pdf/fatigue.pdf](http://www.nccn.org/professionals/physician_gls/pdf/fatigue.pdf)

National Comprehensive Cancer Network. Cancer- and Chemotherapy Induced Anemia. Version 2. 2012. Available from: [http://www.nccn.org/professionals/physician\\_gls/pdf/anemia.pdf](http://www.nccn.org/professionals/physician_gls/pdf/anemia.pdf)

National Institute of Health & National Cancer Institute (2010). Common Terminology Criteria for Adverse Events. Available from : [http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE\\_4.03\\_2010-06-14\\_QuickReference\\_8.5x11.pdf](http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf)

Prabhash, K., Nag, S., Patil, S., & Parikh, P. M. (2011). Optimising management of cancer related anemia. *Indian Journal of Cancer*, 48(1), 1-10.

Rizzo, J. D., Brouwers, M., Hurley, P., Seidenfeld, J., Arcasoy, M. O., Spivak, J. L...Somerfield, M. R. (2010). American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. *Journal of Clinical Oncology*, 28(33), 4996-5010.

Tompkins, S.C., Drake, D., Hoyer, K., & Mock, V. (2004). Evidence-based Practice for fatigue management in adults with cancer: Exercise as an Intervention. *Oncology Nursing Forum*, 31(5) 963-976.

Weis, J. (2011). Cancer-related fatigue: Prevalence, assessment and treatment strategies. *Expert Review of Pharmacoeconomics and Outcomes Research*, 11(4), 441-446.

## Fever and Neutropenia

Alp, S., & Akova, M. (2013). Management of febrile neutropenia in the era of bacterial resistance. *Therapeutic Advances in Infectious Disease*, 1(1), 37–43. doi.org/10.1177/2049936113475610

American Cancer Society; National Comprehensive Cancer Network. Fever and neutropenia: Treatment guidelines for patients with cancer. 2008, March 5: 44. [cited 2008, August 22]. Available from: [http://nccn.org/patients\\_gls/english/pdf/NCCN%20FN%20Guidelines.pdf](http://nccn.org/patients_gls/english/pdf/NCCN%20FN%20Guidelines.pdf)

Angus, D. C., & van der Poll, T. (2013). Severe sepsis and septic shock. *New England Journal of Medicine*, 369(9), 840-851.

Baehner R.L. Overview of neutropenia. 2008, February 20; 17, UpToDate®. [cited 2008, August 22]. Available from: <http://www.utdol.com/utd/content/topic.do?topicKey=whitecel/5073&view=print>

Baehner, R.L. Drug-induced neutropenia and agranulocytosis. 2008, February 20; 14, UpToDate®. [cited 2008, August 22]. Available from: <http://www.utdol.com/utd/content/topic.do?topicKey=whitecel/4821&view=print>

Baehner, R.L. Normal neutrophil development and kinetics. 2008, February 20; 1, UpToDate®. [cited 2008, August 22]. Available from: <http://www.utdol.com/utd/content/topic.do?topicKey=whitecel/6029&view=print>

Baehner, R.L. Neutropenia associated with infections. 2008, February 20; 11, UpToDate®. [cited 2008, August 22]. Available from: <http://www.utdol.com/utd/content/topic.do?topicKey=whitecel/2905&view=print>

Band, J.D. Diagnosis of central venous catheter-related bloodstream infections. 2008, February 20; 5, UpToDate®. [cited 2008, August 22]. Available from: [http://www.utdol.com/utd/content/topic.do?topicKey=hosp\\_inf/8337&view=print](http://www.utdol.com/utd/content/topic.do?topicKey=hosp_inf/8337&view=print)



Bow, E. J. (2013). Infection in neutropenic patients with cancer. *Critical care clinic*, 29 (3), 411-441. Doi:10.1016/j.ccc.2013.03.002

Bow, E. Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for infection. Available from: [http://www.uptodate.com/contents/treatment-and-prevention-of-neutropenic-fever-syndromes-in-adult-cancer-patients-at-low-risk-for-complications?detectedLanguage=en&source=search\\_result&search=Treatment+and+prevention+of+neutropenic+fever+syndromes+in+adult+cancer+patients+at+low+risk+for+infection&selectedTitle=1%7E150&provider=noProvider](http://www.uptodate.com/contents/treatment-and-prevention-of-neutropenic-fever-syndromes-in-adult-cancer-patients-at-low-risk-for-complications?detectedLanguage=en&source=search_result&search=Treatment+and+prevention+of+neutropenic+fever+syndromes+in+adult+cancer+patients+at+low+risk+for+infection&selectedTitle=1%7E150&provider=noProvider)

Bow, E., & Wingard, J.R. Overview of neutropenic fever syndromes. 2013. Available from: [http://www.uptodate.com/contents/overview-of-neutropenic-fever-syndromes?detectedLanguage=en&source=search\\_result&search=Overview+of+neutropenic+fever+syndromes&selectedTitle=1%7E150&provider=noProvider](http://www.uptodate.com/contents/overview-of-neutropenic-fever-syndromes?detectedLanguage=en&source=search_result&search=Overview+of+neutropenic+fever+syndromes&selectedTitle=1%7E150&provider=noProvider)

Bratton, S., & Iannotta, J. A. (2017). Nutritional Interventions for Managing Adverse Effects. *Oncology Nurse Advisor*, 8(6), 22-26.

Cameron, D. (2009). Management of chemotherapy-associated febrile neutropenia. *British Journal of Cancer*, 101(Suppl 1), S18–S22. <http://doi.org/10.1038/sj.bjc.6605272>

Campbell, J.M., Stephenson, M. D., Bateman, E., Peters, M.J., Keefe, D. M., & Bowen, J. M. (2017). Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. *The Pharmacogenomics Journal*, 17(1), 21-28. doi:10.1038/tpj.2-16.58.

Carmona-Bayonas, A., Jiménez-Fonseca, P., Virizuela Echaburu, J., Antonio, M., Font, C., Biosca, M., . . . Ayala de la Peña, F. (2015). Prediction of serious complications in patients with seemingly stable febrile neutropenia: Validation of the clinical index of stable febrile neutropenia in a prospective cohort of patients from the FINITE study. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, 33(5), 465-471. 10.1200/JCO.2014.57.2347

Caselli, D., Cesaro, S., & Aricò, M. (2016). Biosimilars in the management of neutropenia: focus on filgrastim. *Biologics : Targets & Therapy*, 10, 17–22. <http://doi.org/10.2147/BTT.S73580>

Clark, R. T., Bird, S., Kakuchi I., Littlewood, T.J., & van Hamel Parsons, V. (2015). The signs, symptoms and help-seeking experiences of neutropenic sepsis patients before they reach hospital: a qualitative study. *Supportive care in cancer: official journal of the multinational association of supportive care in cancer*, 23 (9), 2687-2694. Doi:10.1007/s00520-015-2631-y

Coates, T. D. Overview of Neutropenia. 2013. Available from: [http://www.uptodate.com/contents/overview-of-neutropenia?detectedLanguage=en&source=search\\_result&search=Overview+of+neutropenia&selectedTitle=1%7E150&provider=noProvider](http://www.uptodate.com/contents/overview-of-neutropenia?detectedLanguage=en&source=search_result&search=Overview+of+neutropenia&selectedTitle=1%7E150&provider=noProvider)

Coates, T.D., & Baehner, R.L. Laboratory evaluation of neutropenia and neutrophil dysfunction. 2008, February 20; 17, UpToDate®. [cited 2008, August 22]. Available from: <http://www.utdol.com/utd/content/topic.do?topicKey=whitecel/9663&view=print>

Cooksley, T., Holland, M., & Klastersky, J. (2015). Ambulatory outpatient management of patients with low risk febrile neutropenia. *Acute medicine*, 14(4), 178-181.

Cortés de Miguel, S., Calleja-Hernández, M. Á., Menjón-Beltrán, S., & Vallejo-Rodríguez, I. (2015). Granulocyte colony-stimulating factors as prophylaxis against febrile neutropenia. *Supportive Care in Cancer*, 23(2), 547-559. doi:10.1007/s00520-014-2459-x

DeMille, D., Deming, P., Lupinacci, P., & Jacobs, L.A. (2006). The effect of the neutropenic diet in the outpatient setting: A pilot study. *Oncology Nursing Forum*, 33(2), p. 337.

Do, T., Medhekar, R., Bhat, R., Chen, H., Niravath, P., & Trivedi, M.V. (2015). The risk of febrile neutropenia and the need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early stage breast cancer patients: a meta analysis. *Breast Cancer Research and treatment*, 153(3), 591-597. Doi:10.1007/s10549-015-3531-z

Donohue, R. (2006). Development and implementation of a risk assessment tool for chemotherapy-induced neutropenia. *Oncology Nursing Forum*, 33(2), p. 347.

Evans, S. E., & Ost, D.E. (2015). Pneumonia in the neutropenic cancer patient. *Current opinion in pulmonary medicine*, 21(3), 260-271. Doi:10.1097/MCP.0000000000000156

Fust K., Parthan A., Maschio M., Gu Q., Li X., Lyman G.H., et al. (2017). Granulocyte colony-stimulating factors in the prevention of febrile neutropenia: Review of cost-effectiveness models. *Expert Review of Pharmacoeconomics and Outcomes Research*, 17(1), 39-52. doi:<http://dx.doi.org/10.1080/14737167.2017.1276829>

Halas, R., Jacob, C., Badwal, K., & Mir, R. (2017). IDCases: Rare case of rhizobium radiobacter bioprosthetic mitral valve endocarditis. Elsevier. doi:10.1016/j.idcr.2017.08008

Jacob, L. A., Lakshmaiah, K. C., Govindbabu, K., Suresh, T. M., Lokanatha, D., Sinha, M., & ... Jayashree, R. S. (2014). Clinical and microbiological profile of febrile neutropenia in solid tumors and hematological malignancies at a tertiary cancer care center in South India. *Indian Journal Of Cancer*, 51(4), 464-468. doi:10.4103/0019-509X.175330

Kallinich, T., Gattorno, M., Grattan, C.E., de Koning, H.D., Traidl-Hoffmann, C., Feist, E., & Simon, A. (2013). Unexplained recurrent fever: when is autoinflammation the explanation? *Allergy*, 68(3), 285-296. doi:10.1111/all.12084,

Keng, M.K., & Sekeres, M. A. (2013). Febrile neutropenia in hematologic malignancies. *Current hematologic malignancy report*, 8(4), 370-378. doi:10.1007/s00134-015-3965-0

Klastersky, J. A., & Meert, A. (2016). Understanding the risk for infection in patients with neutropenia. *Intensive Care medicine*, 42(2), 268-270. doi:10.1007/s00134-015-3965-0

Klastersky, J., Paesmans, M., Rubinstein, E.B., Boyer, M., Elting, L., Feld, R., Gallagher, J., Herrstedt, J., Rapoport, B., Rolston, K., & Talcott, J. (2000). Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. *Journal of Clinical Oncology*, 18(16), 30-38.

Larson, R.A. Prophylaxis of infection during chemotherapy-induced neutropenia. 2008, February 20; 11, UpToDate®. [cited 2008, August 22]. Available from: <http://www.utdol.com/utd/content/topic.do?topicKey=chemgen/4403&view=print>

Lee, S. M., & An, W. S. (2016). New clinical criteria for septic shock: Serum lactate level as new emerging vital sign. *Journal of Thoracic Disease*, 8(7), 1388

Li, W., Kwok, C., Chan, D., Wang, F., & Tse, L. (2017). Breast cancer research and treatment: Weak circadian rhythm increases neutropenia risk among breast cancer patients undergoing adjuvant chemotherapy. Springer. 10.1007/s10549-017-4614-9

Loizidou, A., Aoun, M., & Klastersky, J. (2016). Fever of unknown origin in cancer patients. *Critical review in oncology/hematology*, 101125-130. doi:10.1016/j.critrevonc.2016.02.015.

Lopez, F.A., & Sanders, C.V. Fever and rash in non-HIV immunocompromised hosts. 2008, February 20; 19, UpToDate®. [cited 2008, August 22]. Available from: <http://www.utdol.com/utd/content/topic.do?topicKey=immuninf/8254&view=print>

Lyman, G. H., Abella, E., & Pettengell, R. (2014). Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review. *Critical review in oncology/hematology*, 90(3),190-199. doi:10.1016/critrevonc.2013.12.006

Marty, F.M., Lee, S.J., Fahey M.M., Alyea, E.P., Soiffer, J.H., & Baden, L.R. (2003). Infliximab use in patients with sever graft-versus-host disease and other emerging risk factors of non-candidia invasive fungal infection in allogeneic hematopoietic stem cell transplant recipients; A cohort study. *Blood*, 102(8), 27-68.

Merck Manuals Online Medical Library. The Merck Manual – for Health Care Professionals: Neutropenia. 2005, 2008, February 20, 9, Merck & Co., Inc., Whitehouse Station, NJ. [cited 2008, August 22]. Available from: <http://www.merck.com/mmpe/print/sec11/ch132/ch132b.html>

National Cancer Institute. Common Terminology Criteria for Adverse Events. 2007, January 23;72, US National Institutes of Health. [cited 2008, August 22]. Available from: <http://ctep.cancer.gov/forms/CTCAEv3.pdf>

National Comprehensive cancer Network. Clinical Practice Guidelines in Oncology™. Prevention and treatment of cancer-related infections. 2013 Version 1. Available from: [http://www.nccn.org/professionals/physician\\_gls/f\\_guidelines.asp#infections](http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#infections)

National Institute for Health and Clinical Excellence. Neutropenic sepsis: Prevention and management of neutropenic sepsis in cancer patients. 2012. Available from: <http://www.guideline.gov/content.aspx?id=38445>

Neutropenia Support Association Inc. What is neutropenia? 2008, February 20; 5, Neutropenia Support Association Inc., [cited 2008, August 22]. Available from: <http://www.neutropenia.ca/about/index.html>

Neutropenia Support Association Inc. Chemotherapy and Neutropenia. 2008, February 20, 3, Neutropenia Support Association Inc. [cited 2008, August 22]. Available from: <http://www.neutropenia.ca/about/chemotherapy.html>

Neutropenia Support Association Inc. Optimizing your chemotherapy treatment. 2008, February 20; 1, Neutropenia Support Association Inc. [cited 2008, August 22]. Available from: <http://www.neutropenia.ca/about/optimizing.html>

Neutropenia Support Association Inc. Patient evaluation. 2008, February 20; 3, Neutropenia Support Association Inc. [cited 2008, August 22]. Available from: [http://www.neutropenia.ca/about/patient\\_evaluation.html](http://www.neutropenia.ca/about/patient_evaluation.html)

Nesher, L., & Rolston, K.I. (2014). The current spectrum of infection in cancer patients with chemotherapy related neutropenia. *Infection*, 42(1), 5-13. doi:10.1007/s15010-013-0525-9.

Neviere, R. Pathophysiology of sepsis. 2008, February 20; 15, UpToDate®. [cited 2008, August 22]. Available from: <http://www.utdol.com/utd/content/topic.do?topicKey=whitecel/2905&view=print>

Oncology Nursing Society. Neutropenia - About cancer-related neutropenia. Available from: <http://www.cancersymptoms.org/neutropenia/key.shtml>. Accessed February 20, 2008.

Oncology Nursing Society. Neutropenia - A complete blood count (CBC). Available from: <http://www.cancersymptoms.org/neutropenia/how.shtml>. Accessed February 20, 2008.

Oncology Nursing Society. Neutropenia - Risks associated with neutropenia. Available from: <http://www.cancersymptoms.org/neutropenia/risks.shtml>. Accessed February 20, 2008.

Oncology Nursing Society. Neutropenia - Causes of neutropenia. Available from: <http://www.cancersymptoms.org/neutropenia/causes.shtml>. Accessed February 20, 2008.

Oncology Nursing Society. Neutropenia - Prevention of Neutropenia. Available from: <http://www.cancersymptoms.org/neutropenia/prevention.shtml>. Accessed February 20, 2008.

Oncology Nursing Society. Neutropenia - Methods of managing cancer related neutropenia. Available from: <http://www.cancersymptoms.org/neutropenia/methods.shtml>. Accessed February 20, 2008.

Oncology Nursing Society. Neutropenia - Dietary considerations. Available from: <http://www.cancersymptoms.org/neutropenia/dietary.shtml>. Accessed February 20, 2008.

Pasternack, M.S. Clinical features, management, and prevention of sepsis in the splenectomized patient. 2007; Available from: <http://www.utdol.com/utd/content/topic.do?topicKey=immuninf/5797&view=print>. Accessed February 20, 2008.

People living with cancer (website). Neutropenia. Available from: <http://plwc.org/PLWC/Diagnosis+and+Treatment/Treating+Cancer/Managing+Side+Effects/Neutropenia>. Accessed February 20, 2008.

People living with cancer (website). Infection. Available from: <http://plwc.org/PLWC/Diagnosis+and+Treatment/Treating+Cancer/Managing+Side+Effects/Infection>. Accessed February 20, 2008.

Robbins, G.K. Fever in the neutropenic adult patient with cancer. 2007; Available from: <http://www.utdol.com/utd/content/topic.do?topicKey=immuninf/4688&view=print>. Accessed February 20, 2008.

Sugar, A.M. Clinical features and diagnosis of invasive aspergillosis. 2007; Available from: [http://www.utdol.com/utd/content/topic.do?topicKey=fung\\_inf/6397&view=print](http://www.utdol.com/utd/content/topic.do?topicKey=fung_inf/6397&view=print). Accessed February 20, 2008.

U.S. National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) Program. Blood Cell Lineage. 2000; Available at: [http://www.training.seer.cancer.gov/ss\\_module08\\_lymph\\_leuk/leuk\\_unit02\\_sec03\\_cell\\_lineage.html](http://www.training.seer.cancer.gov/ss_module08_lymph_leuk/leuk_unit02_sec03_cell_lineage.html). Accessed March 5, 2008.

Weinstein, R. A., Thom, K. A., Kleinberg, M., & Roghmann, M. (2013). Infection prevention in the cancer center. *Clinical Infectious Diseases*, 57(4), 579-585.

## Intimacy and Sexuality

Annon, J.S. Behavioural treatment of sexual problems. Honolulu: Enabling Systems; 1974.

Bevan, D., & Thompson, N. (2003). The social basis of loss and grief: Age, disability and sexuality. *Journal of Social Work*, 3(2), 179-94.

Bolte, S., & Zebrack, B. (2008). Sexual issues in special populations: Adolescents and young adults. *Seminars in Oncology Nursing*. 24(2), 115-119.

Bruner, D.W., & Berk, L. Altered Body Image and Sexual Health. In: Yarbro CH, Frogge MH, Goodman M, editors. *Cancer Symptom Management*. 3rd ed. Sudbury, Massachusetts: Jones and Bartlett Publishers; 2004: 596-634.

- Caffo, O., & Amichetti, M. (1999). Evaluation of sexual life after orchidectomy followed by radiotherapy for early stage seminoma of the testis. *British Journal of Urology*, 83, 462-468.
- Canadian Association of Nurses in Oncology/ Association canadienne des infirmières en oncologie (CANO/ACIO). Practice Standards and Competencies for the Specialized Oncology Nurse. 2006: 1-47.
- Canadian Cancer Society. (2013). Sexuality and Cancer. Retrieved June 18, 2013 from: <http://www.cancer.ca/en/cancer-information/cancer-journey/living-with-cancer/sexuality-and-cancer/?region=bc>
- Carter, J., Lacchetti, C., Anderson, B., Barton, D., Bolte, S., Damast, S.,.....Rowland, J. (2018). Intervention to address sexual problems in people with cancer: American society of clinical oncology clinical practice guideline adaptation of cancer care Ontario guideline. *Journal of Clinical Oncology*. 36(5), 492-513
- Dibble. S., Eliason, M.J., DeJoseph, J.F., & Chinn, P. (2008). Sexual issues in special populations: Lesbian and gay individuals. *Seminars in Oncology Nursing*, 24(2), 127-130.
- Doyle, D. Textbook of Palliative Medicine. Oxford: University Press; 2004
- Ferrell, B., & Coyle, N. Textbook of Palliative Nursing. University Press: Oxford; 2001
- Flay, L.F., & Mathews, J.H.L. (1995). *The effects of radiotherapy and surgery on the sexual function of women treated for cervical cancer. International Journal of Radiation Oncology Biological Physics*, 31(2), 399-404.
- Galbraith, M.E., & Crighton, F. (2008). Alterations of sexual function in men with cancer. *Seminars in Oncology Nursing*. 24(2), 102-114.
- Gamel, C., Hengeveld, M., & Davis, B. (2000). Informational needs about the effects of gynaecological cancer on sexuality: a review of the literature. *Journal of Clinical Nursing*, 9, 678-88.
- Ganz, P.A., Meyerowitz, B.E., & Perez, M.A. Sexual health and functioning after cancer. In Supportive care in cancer: A handbook for oncologists, J. Klastersky, S, Schimpff, H Senn (Eds). New York: Marcel Dekker: New York; 1999; p. 309-328.
- Kotronoulas, G., Papadopoulou, C., & Patiraki, E. (2009). Nurses' knowledge, attitudes, and practices regarding provision of sexual health care in patients with cancer: critical review of the evidence. *Support Care Cancer*, 17, 479–501.
- Horden, A.J., & Currow, D.C. (2003) A patient centered approach to sexuality in the face of life-limiting illness. *Medical Journal of Australia*, 179, S8-S11.
- Horden, A.J. (2008). Intimacy and sexuality after cancer: A critical review of the literature. *Cancer Nursing*, 31(2), E9-E17.
- Hughes, M.K. (2008). Alterations of sexual function in women with cancer. *Seminars in Oncology Nursing*, 24(2), 91-101.
- IPODE Project, Canadian Association of Psychosocial Oncology, *Sexual Health in Cancer, 2011*, Continuing Education Course.
- Kagan, S.H., Holland, N., & Chalian, A.A. (2008). Sexual issues in special populations: Geriatric oncology – sexuality and older adults. *Seminars in Oncology Nursing*, 24(2), 120-126.
- Katz, A. (2011). Breast Cancer and Women's Sexuality. *American Journal of Nursing*, 111(4), p. 63-67.
- Katz , A. Breaking the Silence on Cancer and Sexuality: A Handbook for Healthcare Providers. Oncology Nursing Society; USA; 2007.

- Kozier, B., Erb, G., Blais, K., & Wilkinson, J.M. Fundamentals of Nursing: Concepts, Process and Practice, 5<sup>th</sup> ed. Addison-Wesley Longman Inc, California; 2001.
- Krebs, L. (2006). What should I say? Talking with patients about sexuality issues. *Clinical Journal of Oncology Nursing*, 10(3), 313-315.
- Krebs, L.U. (2008). Sexual assessment in cancer care: Concepts, methods, and strategies for success. *Seminars in Oncology Nursing*, 24(2), 80-90.
- Langhorne, M., Fulton, J., & Otto, S. (2007). *Oncology Nursing*. 5<sup>th</sup> Edition. St. Louis, MO: Mosby.
- Lemieux, L., Kaiser, S., Pereira, J., & Meadows, L.M. (2004). Sexuality in palliative care: Patient perspectives. *Palliative Medicine*, 18, 630-637.
- Leung, M., Goldfarb, S., & Dizon, D. (2016). Communication about sexuality in advanced illness aligns with a palliative care approach to patient-centered care. *Curr Oncol Rep*. 18(11), 1-6
- Lindau, S., Abramsohn, E., Baron, S., Florendo, J., Haefner, H., Jhingran, A., ... Streicher, L. (2016). Physical examination of the female cancer patient with sexual concerns: what oncologists and patients should expect from consultation with specialist. *A Cancer Journal for Clinicians*. 66, 241-263
- Mick, J., Hughes, M., & Cohen, M.Z. (2004). Using the BETTER model to assess sexuality. *Clinical Journal of Oncology Nursing*, 8(1), 84-86.
- National Cancer Institute. Sexuality and Reproductive Issues PDQ Health Professional Version. June 2012. Available from:  
<http://www.cancer.gov/cancertopics/pdq/supportivecare/sexuality/HealthProfessional>
- Oliviere, D., & Monroe, B. (Eds.). Death, Dying and Social Differences. 2004. Oxford University Press, ISBN: 0-19-852775-6.
- Rando, T. (1984). Grief, dying and death: Clinical interventions for caregivers. Champaign, IL: Research Press; 1984.
- Rice, A.M. (2000). Sexuality in cancer and palliative care 1: effects of disease and treatment. *International Journal of Palliative Care Nursing*, 6(8), 392-397.
- Shell, J.A. (2008). Sexual issues in the palliative care population. *Seminars in Oncology Nursing*, 24(2), 131-134
- Schover, R., von Essenbach, A.C., Smith, D.B., & Gonzalez, J. (1984). Sexual rehabilitation of urologic cancer patients: A practical approach. *Cancer Journal Clinics*, 32, 66-74
- Tierney, K. (2008). Sexuality: A quality-of-life issue for cancer survivors. *Seminars in Oncology Nursing*, 24(2), 71-79.
- Wilmoth, M.C. (2006). Life after cancer: What does sexuality have to do with it? *Oncology Nursing Forum*, 33(5), 905-910.
- Wilmoth, M.C., & Ross, J.A. (1997). Women's perception: breast cancer treatment and sexuality. *Cancer Practice: A Multidisciplinary Journal of Cancer Care*, 5(6), 353-359.
- Winningham, M.L., Nail, L.M., Burke, M.B., Brophy, L., Cimprich, B., Jones, L.S., Pickard-Holley, S., et al. (1994). Fatigue and the cancer experience: The state of the knowledge. *Oncology Nursing Forum*, 21(1), 23-36.

## Lymphedema

- Appollo, K. (2007). Lower-extremity lymphedema in a patient with gynecologic Cancer. *Oncology Nursing Forum*, 34(5), 937-939.
- Armer, J.M., Stewart, B.R. (2005). A comparison of four diagnostic criteria for lymphedema in a post-breast cancer population. *Lymphatic Research and Biology*. 3(4), 208-217.
- Becker, C., Assouad, J., Riquet, M., et al. (2006). Post mastectomy lymphedema: Long-term results following microsurgical lymph node transplantation. *Annals of Surgery* 243(3), 313-315.
- Bruns, F., Micke, O., & Bremer, M. (2003). Current status of selenium and other treatments for secondary lymphedema. *The Journal of Supportive Oncology*, 1(2), 121-130.
- Carter, B.J. (1997). Women's experiences of lymphedema. *Oncology Nursing Forum*. 24(5), 875-882.
- Chang, C., & Cormier, J. (2013). Lymphedema interventions: exercise, surgery and compression devices. *Seminars in Oncology Nursing*, 29(1), pp. 28-40. <https://doi.org/10.1016/j.soncn.2012.11.005>
- Cheifetz, O., & Haley, L. (2010). Management of secondary lymphedema related to breast cancer. *Canadian Family Physician*, 56, 1277-84.
- Cheville, A. (2006). Lymphoscintigraphy: It's role in lymphedema management. *LymphLink (National Lymphedema Network)* 18 (1).
- Dixon, B., & Weiler, M. (2016). Bridging the divide between pathogenesis and detection in lymphedema. *Semin Cell Dev Biol*, 38 pp. 75-82. doi: [[10.1016/j.semcdb.2014.12.003](https://doi.org/10.1016/j.semcdb.2014.12.003)]
- Doscher, M., Shreiber, J., Weichman, K., Garfein, E. (2016). Update on post-mastectomy lymphedema management. *The Breast Journal*, 22(5), p 553-560. DOI:[10.1111/tbj.12625](https://doi.org/10.1111/tbj.12625)
- Doughty, D. B., & Holbrook, R. (2007). Lower-extremity ulcers of vascular etiology. In R. A. Bryant & D. Nix (Eds.), *Acute & chronic wounds: Current management concepts* (3rd ed., pp. 298-303). St. Louis: Mosby-Elsevier.
- Dynamed. Lymphedema. (2013). Available from: <http://web.ebscohost.com/dynamed/detail?vid=3&sid=168b877d-d53a-4344-adb8-dfabbc99589%40sessionmgr104&hid=112&bdata=JnNpdGU9ZHluYW1lZC1saXZlJnNjb3BIPXNpdGU%3d#db=dme&AN=115374>
- Ehrlich, A., Vinje-Harrewijn, A., & McMahon, E. (2005). Living well with lymphedema. *Lymph Notes, San Francisco, CA*.
- Fu, M., & Kang, Y. (2013). Psychosocial impact of living with cancer-related lymphedema. *Seminars in Oncology Nursing*, 29(1), pp. 50-60. <https://doi.org/10.1016/j.soncn.2012.11.007>
- Fu, M. (2005). Breast cancer survivors' intentions of managing lymphedema. *Cancer Nursing*, 28(6), 446-457.
- Golshan, M. (2006). Lymphedema in breast cancer patients: Declining, but awareness still needed. [www.SupportiveOncology.net](http://www.SupportiveOncology.net) 4(2), 71.
- Hadway, P., Lynch, M., Corbishley, C., et al. (2006). Squamous cell carcinoma of the penis in a patient with chronic isolated penile lymphoedema. *Urologia Internationalis*, 76, 87-88.
- Johansson, K., Holmstrom, H., Nilsson, I., et al. (2003). Breast cancer patients' experiences of lymphoedema. *Scand J Caring Sci*. 17, 35-42.

- King, B. (2006). Diagnosis and management of lymphoedema. *Nursing Times*, 102, 49-49.
- Kligman, L., Wong, R., Johnston, M. et al (2003). The treatment of lymphedema related to breast cancer – evidence summary report. *Cancer Care Ontario & the Ontario Ministry of Health and Long-term Care*. [www.cancercare.on.ca](http://www.cancercare.on.ca)
- Kornblith, A.B., Herndon, J.E., Weiss, R.B. et al. (2003). Long-term adjustment of survivors of early-stage breast carcinoma, 20 years after adjuvant chemotherapy. *Cancer*, 98(4), 679-689.
- Lacovara, J.E., & Yoder, L.H. (2006). Secondary lymphedema in the cancer patient. *MEDSURG Nursing*, 15(5), 302-306.
- Lockwood-Rayermann, S. (2007). Lymphedema in gynecologic cancer Survivors. An area for exploration? *Cancer Nursing*, 30(4), 11-18.
- Lymphoedema Framework. (2006). *Best practice for the management of lymphoedema. International consensus*. Retrieved June 8, 2009, from <http://www.lymphovenous-canada.ca/>
- MacLaren, J. (2001). Skin changes in lymphoedema: Pathophysiology and management options. *International Journal of Palliative Nursing*, 7(8), 381-388.
- MacLaren, J.A. (2003). Models of lymphoedema service provision across Europe: Sharing good practice. *International Journal of Palliative Nursing*, 9(12), 538-543.
- McNeely, M., et al. (2004). The addition of manual lymph drainage to compression therapy for breast cancer related lymphedema: A randomized controlled trial. *Breast Cancer Research and Treatment*, 86(2), 95-106.
- McNeely, M. et al. (2005). The addition of manual lymph drainage to compression therapy for breast cancer related lymphedema: A randomized controlled trial. [www.lymphovenous-canada.ca/crosscancerstudy.htm](http://www.lymphovenous-canada.ca/crosscancerstudy.htm)
- Mohler, E., & Mehrara, B. (2017). Clinical features and diagnosis of peripheral lymphedema. UpToDate. Retrieved from: [https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-peripheral-lymphedema?search=clinical%20features%20lymphedema&source=search\\_result&selectedTitle=1~150&usage\\_type=default&display\\_rank=1](https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-peripheral-lymphedema?search=clinical%20features%20lymphedema&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1)
- Mohler, E. & Mehrara, B. (2016). Breast cancer associated lymphedema. UpToDate. Retrieved from: [https://www.uptodate.com/contents/breast-cancer-associated-lymphedema?search=breaste%20cancer%20lymphedema&source=search\\_result&selectedTitle=2~150&usage\\_type=default&display\\_rank=2](https://www.uptodate.com/contents/breast-cancer-associated-lymphedema?search=breaste%20cancer%20lymphedema&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2)
- Mohler, E. R., & Mondry, T. E. (2013). Prevention and Treatment of Lymphedema. Available from: [http://www.uptodate.com/contents/prevention-and-treatment-of-lymphedema?source=search\\_result&search=prevention+and+treatment+of+lymphedema&selectedTitle=1%7E138](http://www.uptodate.com/contents/prevention-and-treatment-of-lymphedema?source=search_result&search=prevention+and+treatment+of+lymphedema&selectedTitle=1%7E138)
- Mohler, E. R., & Mondry, T. E. (2013). Clinical Manifestations and Diagnosis of Lymphedema. Available from: [http://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-lymphedema?source=search\\_result&search=clinical+manifestations+and+diagnosis+of+lymphedema&selectedTitle=1%7E138](http://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-lymphedema?source=search_result&search=clinical+manifestations+and+diagnosis+of+lymphedema&selectedTitle=1%7E138)
- Mortimer, P., Rockson, S. (2014). New developments in clinical aspects of lymphatic disease. *The Journal of Clinical Investigation*, 124(3), pp. 915-921. doi: [10.1172/JCI71608]
- Mosely, A., & Piller, N. (2002). The assessment and care of the patient with secondary limb lymphoedema. *ANJ Clinical Update* 53, 1-4.



Moseley, A., Piller, N., & Carati, C. (2005). The effect of gentle arm exercise and deep breathing on secondary arm lymphedema. *Lymphology* 38, 136-145.

Muscari, E. (2004). Lymphedema: responding to our patients' needs. *Oncology Nursing Forum*, 31(5), 905-912.

National Cancer Institute. Common Terminology Criteria for Adverse Events. Version 4.03. 2010. Available from :

[http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE\\_4.03\\_2010-06-14\\_QuickReference\\_8.5x11.pdf](http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf)

National Cancer Institute, US National Institute of Health. Lymphedema (PDQ®) – Health professional version. 2013. Available from: <http://www.cancer.gov/cancertopics/pdq/supportivecare/lymphedema/healthprofessional>

Morgan, P.A., Moody, M., Franks, P.J. et al. (2005). Assessing community nurses' level of knowledge of lymphoedema. *British Journal of Nursing*, 14(1), 8-13.

National Lymphedema Network. (2006). Position statement of the national lymphedema network.

[www.lymphnet.org/pdfDocs/nlntreatment.pdf](http://www.lymphnet.org/pdfDocs/nlntreatment.pdf)

[Oncology Nursing Society \(2008\) PEP Guidelines Lymphedema ONS Pittsburgh.](#)

Oremus, M., Dayes, I., Walker, K., & Raina, P. (2012). Systematic review: Conservative treatments for secondary lymphedema. *BMC Cancer*, 12(6), 1-15.

Piller, N., & Birrell, S. (2003). How to treat lymphedema. [www.australiandoctor.com.au](http://www.australiandoctor.com.au). June, 1-8.

Renshaw, M. (2007). Lymphorrhoea: 'Leaky legs' are not just the nurse's problem. *The Lymphoedema Supplement*. April 518-521.

Ridner, S.H. (2002). Breast cancer lymphedema: Pathophysiology and risk reduction guidelines. *Oncology Nursing Forum*, 29, 1285-1291.

Ridner, S.H. (2006). Pretreatment lymphedema education and identified educational resources in breast cancer patients. *Patient Education and Counseling*, 61, 72-79.

Ridner, S. H., Fu, M. R., Wanchai, A., Stewart, B. R., Armer, J. M., & Cormier, J. N. (2012). Self-management of lymphedema: A systematic review of the literature from 2004 to 2011. *Nursing Research*, 61(4):291-299.

Round, T., Hayes, S.C., & Newman, B. (2006). How do recovery advice and behavioural characteristics influence upper-body function and quality of life among women 6 months after breast cancer diagnosis? *Support Care Cancer*, 14, 22-29.

Schmitz, K.H, et. al. (2009). Weight lifting in women with breast-cancer related lymphedema. *The New England Journal of Medicine*, 361, pp 664-673. DOI: 10.1056/NEJMoa0810118

Simmins Holcomb, S. (2006). Putting the squeeze on lymphedema. *Nursing Made Incredibly Easy!* March/April.

Szuba, A. (2002). Decongestive lymphatic therapy for patients with breast carcinoma-associated lymphedema. A randomized, prospective study of a role for adjunctive intermittent pneumatic compression. *Cancer* 95, 2260-2267.

Taylor, R., Jayashinghe, U., Koelmeyer, L. et al. (2006). Reliability and validity of arm volume measurements for assessment of lymphedema. *Journal of the American Physical Therapy Association*, 86, 205-214.

Thomas-MacLean, R., Miedema, B., & Tatemichi, S.R. (2005). Breast cancer-related lymphedema – Women's experiences with an underestimated condition. *Canadian Family Physician*, 51, 242-243.

Tobin, M.B., Psych, M.R., & Lacey, H.J. (1993). The psychological morbidity of breast cancer-related arm swelling. *Cancer* 72(11), 3248-3252.

Toole, K., Jammallo, L., Skolny, M., Miller, C., Elliott, K., & Taghian, A. (2013). Lymphedema following treatment for breast cancer: a new approach to an old problem. *Crit Rev Oncol Hematol*, 88(2), pp. 437-446. doi: [10.1016/j.critrevonc.2013.05.001](https://doi.org/10.1016/j.critrevonc.2013.05.001)

Wanchai, A., Armer, J., & Stewart, B. (2013). Complementary and alternative medicine and lymphedema. *Seminars in Oncology Nursing*, 29(1), pp. 41-49. <https://doi.org/10.1016/j.soncn.2012.11.006>

Wilburn, O., Wilburn, P., & Rockson, S. (2006). A pilot, prospective evaluation of a novel alternative for maintenance therapy of breast cancer-associated lymphedema, *BMC Cancer*, 6, 84, 1-10.

Williams, A.F., Moffatt, C.J., & Franks, P.J. (2004) A phenomenological study of the lived experiences of people with lymphoedema. *International Journal of Palliative Nursing*, 10 (6), 279-286.

Woods, M., Smith, J., Cameron, F., & Claughton, D. (2008). Air travel and upper limb lymphedema: What advice should patients be given? *Cancer Nursing practice*, 7(9), 29-33.

Zuther, J. E. (2005). Lymphedema management: The comprehensive guide for practitioners New York, NY: Thieme Medical Publishers, Inc. pp. 236-237.

## Malignant Wounds

Armstrong, DG. and Meyr, AJ.(2014) Basic principles of wound management. In T. Post (Ed) UpToDate, Waltham, Mass.: UpToDate. Retrieved from [www.uptodate.com](http://www.uptodate.com)

Bates-Jensen, B.M., Seaman, S., and Early, L. (2006). Skin Disorders: Tumor Necrosis, Fistulas and Stomas. In Betty R. Ferrell and Nessa Coyle (Eds.), *Textbook of Palliative Nursing* 2nd edition (pp.329-343) Oxford: Oxford University Press.

British Columbia Provincial Nursing Skin and Wound Committee Guideline(2014). *Wound bed preparation for healable and non-healable wounds*. Retrieved from <https://www.clwk.ca/buddydrive/file/guideline-wound-bed-preparation/>

Benbow, M., (2008). Exuding wounds. *Journal of Community Nursing*. 22, (11), pp. 20-26.

Cochran, S., & Jakubek, P. R. (2010). Malignant cutaneous diseases. In M. L. Haas & G. J. Moore-Higgs (Eds.), *Principles of skin care and the oncology patient* (pp.77-100). Pittsburgh: PA, Oncology Nursing Society.

Dealey, C. (2012). *The care of wounds: A guide for nurses*. 4<sup>th</sup> edition Wiley-Blackwell.

Fromantin, I; Watson, S; Baffie, A; Rivat, A; Falcou, M; Kriegel, I; de Rycke Ingenior, Y; (2014). A prospective, descriptive cohort study of malignant wound characteristics and wound care strategies in patients with breast cancer. *Ostomy Wound Management*, 60 (6): 38-48.

Grocott, P., (2007). Care of patients with fungating malignant wounds. *Nursing Standard*. 21 (24), pp. 57- 66.

Grocott,P., & Robinson, V. (2010). Skin problems in palliative care –nursing aspects. In G. Hanks, N.I. Cherney, N.A. Christakis, M. Fallon, S. Kaasa and R. Portenoy (Eds.), *Oxford Textbook of Palliative Medicine* 4th edition (pp.961-971) Oxford: Oxford University Press.

Guo, S., & DiPietro, L. A. (2010). Factors Affecting Wound Healing. *Journal of Dental Research*, 89(3), 219–229. doi:10.1177/0022034509359125

- Haisfield-Wolfe, M.E. & Baxendale-Cox, L.M. (1999). Staging of malignant cutaneous wounds: A Pilot Study. *Oncology Nursing Forum*. 26 (6), pp. 1055-1064.
- Haisfield-Wolfe, M.E. & Rind, C. (1997). Malignant cutaneous wounds: A Management Protocol. *Ostomy/Wound Management*. 43 (1), pp. 56-66.
- Hampton, S., (2008). Malodorous fungating wounds: how dressing alleviate symptoms. *Wound Care*. June 2008, pp. S31-S38.
- Harmer, V., (2008). Breast cancer. Part 3: advanced cancer and psychological implications. *British Journal of Nursing*. 17 (17), pp. 1088-1098.
- Hawthorn M (2010) Caring for a patient with a fungating malignant lesion in a hospice setting: Reflecting on practice. *International Journal Palliative Nursing* 16(2), 70–6
- Laverty, D., (2003). Fungating wounds: informing practice through knowledge/theory. *British Journal of Nursing*. 12 (15), pp. S29-S40.
- Lazelle-Ali, C., (2007). Psychological and physical care of malodorous fungating wounds. *British Journal of Nursing*. 16 (15), pp. S16-S24.
- Lloyd, H., (2008). Management of bleeding and malodour in fungating wounds. *Journal of Community Nursing*. 22 (8/9), pp. 28-32.
- McDonald, A., & Lesage, P., (2006). Palliative Management of Pressure Ulcers and Malignant Wounds in Patients with Advanced Illness. *Journal of Palliative Medicine*. 9 (2), pp. 285-295.
- Merriam-Webster's Medical Dictionary, (2007). Merriam-Webster, Inc.  
<http://www.merriam-webster.com/medical/body%20image>. Accessed on January 5, 2011.
- Milne, C., Corbett, D., & Dubuc, D., (2003). Wound, ostomy and continence nursing secrets.  
[http://books.google.ca/books?id=xSCuk2ySfwAC&dq=psi+to+cleanse+wounds&source=gbs\\_navlinks\\_s](http://books.google.ca/books?id=xSCuk2ySfwAC&dq=psi+to+cleanse+wounds&source=gbs_navlinks_s).  
 Visited on February 24, 2011.
- Nazarko, L., (2006). Malignant fungating wounds. *Nursing & Residential Care*. 8 (9), pp. 404- 406.
- Perry, A., & Potter, P., (2010). *Clinical Nursing Skills & Techniques*. Seventh Addition. Mosby, Inc., St. Louis, Missouri, USA. pp. 1143-1145.
- Perry, A.G., Potter, P. A., & Ostendorf, W. R. (2014). *Clinical Nursing Skills & Techniques* (8<sup>th</sup> ed.). St Louis, MO: Elsevier. pp. 942-967, 920- 930.
- Probst, S., Arber, A., and Faithfull, S. (2013). Malignant fungating wounds – The meaning of living in an unbounded body. *European Journal of Oncology Nursing*. 17, pp. 38-45.
- Savage, P., & Ganson, C. (2010). Impact of chronic disease on wound healing. In M. L. Haas & G. J. Moore-Higgs (Eds.), *Principles of skin care and the oncology patient* (pp.195- 213). Pittsburgh: PA, Oncology Nursing Society.
- Schulz, V., Kozell, K., Biondo, PD., Stiles, C., Tonkin, K., & Hagan. N.A., (2009). The malignant wound assessment tool: a validation study using a Delphi approach. *Palliative Medicine*. 23, pp. 266-273.
- Seaman, S. (2006) Management of malignant fungating wounds in advanced cancer. *Seminars in Oncology Nursing*, Vol 22, No. 3 (August) pp. 185-193.

Sibbald, G., et al. (2006). Increased bacterial burden and infection: The story of NERDS and STONES. *Advances in Skin and Wound Care*, 19(8): 158.

Taylor, C. (2011). Malignant fungating wounds: A review of the patient and nurse experience. *British Journal of Community Nursing*, S16-22.

Williams, D. T., & Harding, K. (2003). Healing responses of skin and muscle in critical illness. *Critical Care Medicine*, 31 (8) pp S547-S557

doi: 10.1097/01.CCM.0000081430.34066.1D

Wilson, V., (2005). Assessment and management of fungating wounds: a review. *Wound Care*. March 2005, pp. S28-34.

Woo, K., et al. (2009). A cross-sectional validation study using NERDS and STONEES to assess bacterial burden. *Ostomy Wound Management*. 55(8): 40 – 48.

Wound Care Information Network (2013). *Types of wound debridement*. Retrieved on March 10, 2015 from <http://www.medicaledu.com/debridhp.htm>

## Nausea and Vomiting

Basch, E., Prestrud, A.A., Hesketh, P.J., Ktis, M.G., Feyer, P.C., Somerfield, M.R., Chesney, M., Clark-Snow, R.A., Flaherty, A.M., Freundlich, B., Morrow, G., Rao, K.V., Schwartz, R. N., & Lyman, G.H. (2011). Antiemetics: ASCO clinical practice guideline update. *Journal of Clinical Oncology*, 29(31) p. 4189-4198. doi: 10.1200/JCO.2010.34.4614

Barni S., Petrelli F., & Cabiddu, M. (2016). Cardiotoxicity of antiemetic drugs in oncology: An overview of the current state of the art. *Critical Reviews in oncology/hematology*, 102, 125-134. doi:<http://dx.doi.org/10.1016/j.critrevonc.2016.04.012>

Cancer Care Nova Scotia. Guidelines for the management of nausea and vomiting in cancer patients. (2004) (cited 2007, Sept.27) Available from: <http://www.cancercare.ns.ca/media/documents/NauseaVomitingFullVersion.pdf>

Cancer Care Ontario. Symptom management guidelines, (2013). Retrieved December 3, 2013 from: [https://www.cancercare.on.ca/CCO\\_DrugFormulary/Pages/FileContent.aspx?fileId=97475](https://www.cancercare.on.ca/CCO_DrugFormulary/Pages/FileContent.aspx?fileId=97475)

Chiu, L., Chow, R., Popovic, M., Navari, R. M., Shumway, N. M., Chiu, N., . . . DeAngelis, C. (2016). Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis. *Supportive Care in Cancer*, 24(5), 2381-2392. doi:<https://dx.doi.org/10.1007/s00520-016-3075-8>

Chiu, N., Chiu, L., Popovic, M., DeAngelis, C., Pasetka, M., Lutz, S., . . . Chow, E. (2016). Latest advances in the management of radiation-induced pain flare, nausea and vomiting. *Annals of Palliative Medicine*, 5(1), 50-57. doi:<https://dx.doi.org/10.3978/j.issn.2224-5820.2015.08.01>

Dabaghzadeh, F., Khalili, H., & Dashti-Khavidaki, S. (2014). Ginger for prevention or treatment of drug-induced nausea and vomiting. *Current Clinical Pharmacology*, 9(4), 387-394.

Davis, M. P. (2016). New therapies for antiemetic prophylaxis for chemotherapy. *Journal of Community and Supportive Oncology*, 14(1), 11-20. doi:<http://dx.doi.org/10.12788/jcso.0207>

e-CPS [Internet]. Ottawa (ON): Canadian Pharmacists Association; c2014 . Available from: <http://www.e-cps.ca>.

Fraser Health, Hospice Palliative Care Program. Nausea. Hospice Palliative Care Program Symptom Guidelines. 2006, Dec 5; [cited 2008, March]: 1-11. Available from: <http://www.fraserhealth.ca/Services/HomeandCommunityCare/HospicePalliativeCare/Documents/14FHSymptomGuidelinesNausea.pdf>

Fonte C., Fatigoni S., & Roila, F. (2015). A review of olanzapine as an antiemetic in chemotherapy-induced nausea and vomiting and in palliative care patients. *Critical Reviews in oncology/hematology*, 95(2), 214-221. doi:<http://dx.doi.org/10.1016/j.critrevonc.2015.02.010>

Gordon, P., LeGrand, S. B., & Walsh, D. (2014). Nausea and vomiting in advanced cancer. *European Journal of Pharmacology*, 722, 187-191. doi:<https://dx.doi.org/10.1016/j.ejphar.2013.10.010>

Gralla, R. J., Roila, F., Tonato, M., & Herstedt, J. (2011). MASCC/ESMO Antiemetic Guideline . Multinational Association of Supportive Care in Cancer. Perugia, Italy.

Hilarius, D.L., Kloeg, P.H., van der Wall, E., van den Heuvel, J.J.G., Gundy, C.M., & Aaronson, N.K. (2012). Chemo-therapy-induced nausea and vomiting in daily clinical practice: a community hospital based study. *Support Care Cancer*, 20. 107-117. doi: 10.1007/s00520-010-1073-9.

Janicki P.K., & Sugino, S. (2014). Genetic factors associated with pharmacotherapy and background sensitivity to postoperative and chemotherapy-induced nausea and vomiting. *Experimental Brain Research*, 232(Special Issue: Biology and Control of Nausea and Vomiting.), 2613-2625. doi:<http://dx.doi.org/10.1007/s00221-014-3968-z>

Kamen, C., Tejani, M. A., Chandwani, K., Janelins, M., Peoples, A. R., Roscoe, J. A., & Morrow, G. R. (2014). Anticipatory nausea and vomiting due to chemotherapy. *European Journal of Pharmacology*, 722, 172-179. doi:<https://dx.doi.org/10.1016/j.ejphar.2013.09.071>

Kravits, K. G. (2015). Hypnosis for the Management of Anticipatory Nausea and Vomiting. *Journal of the Advanced Practitioner in Oncology*, 6(3), 225-229.

Konno, R. (2010). Cochrane review Summary for Cancer Nursing: Acupuncture-Point Stimulation for chemotherapy-induced nausea or vomiting. *Cancer Nursing*, 33(6), 479-480. doi: 10.1097/NCC.0b013e3181f04bc

Lete I., & Allue, J. (2016). The effectiveness of ginger in the prevention of nausea and vomiting during pregnancy and chemotherapy. *Integrative Medicine Insights*, 11, 11-17. doi:<http://dx.doi.org/10.4137/IMI.S36273>

Malik Z., Baik D., & Schey, R. (2015). The Role of Cannabinoids in Regulation of Nausea and Vomiting, and Visceral Pain. *Current Gastroenterology Reports*, 17(2) (pagination), ate of Pubaton: 2015. doi:<http://dx.doi.org/10.1007/s11894-015-0429-1>

MurrayBrown, F., & Dorman, S. (2015). Haloperidol for the treatment of nausea and vomiting in palliative care patients. *Cochrane Database of Systematic Reviews*, 11

Natale, J. J. (2015). Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis. *Hospital Practice (1995) Hospital Practice*, 43(4), 226-234. doi:<https://dx.doi.org/10.1080/21548331.2015.1077095>

Navari R.M., & Aapro, M. (2016). Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. *New England Journal of Medicine*, 374(14), 1356-1367. doi:<http://dx.doi.org/10.1056/NEJMra1515442>

Navari, R. M. (2014). Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting. *European Journal of Pharmacology*, 722(1), 180-186. doi:<http://dx.doi.org/10.1016/j.ejphar.2013.08.048>

Navari, R. M. (2016). The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting. *Expert Opinion on Drug Safety*, 15(3), 343-356. doi:<http://dx.doi.org/10.1517/14740338.2016.1135899>

National Cancer Institute. (NCI) Nausea and Vomiting (PDQ) Health Professional Version. 2007, August. [cited October 1, 2007] Available from: <http://www.cancer.gov/cancertopics/pdq/supportivecare/nausea/HealthProfessional/page1h>

National Comprehensive Cancer Network. (2011). Clinical Practice Guidelines in Oncology: Antiemesis. Retrieved December 3, 2012 from: [http://www.nccn.org/professionals/physician\\_gls/pdf/antiemesis.pdf](http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf)

National Comprehensive Cancer Network. (NCCN) Clinical practice guidelines in oncology. Antiemesis. (Version 1.0) 2007. [cited October 1, 2007]. Available from: [http://www.nccn.org/professionals/physician\\_gls/PDF/antiemesis.pdf](http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf)

National Comprehensive Cancer Network. (NCCN) Treatment guidelines for patients. (Version 4.0) 2007, January. [cited October 1, 2007]. Available from: [http://www.nccn.org/patients/patient\\_gls/english/nausea\\_and\\_vomiting/2\\_causes.asp](http://www.nccn.org/patients/patient_gls/english/nausea_and_vomiting/2_causes.asp)

National Institute of Health & National Cancer Institute (2010). Common Terminology Criteria for Adverse Events. Available from : [http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE\\_4.03\\_2010-06-14\\_QuickReference\\_8.5x11.pdf](http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf)

Smith, L. A., Azariah, F., Lavender, T. C. V., Stoner, N. S., & Bettioli, S. (2015). Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. *Cochrane Database of Systematic Reviews*, 11

Sommariva, S., Pongiglione, B., & Tarricone, R. (2016). Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: A systematic review. *Critical Reviews in Oncology-Hematology*, 99, 13-36. doi:<https://dx.doi.org/10.1016/j.critrevonc.2015.12.001>

Valentine, K. A., & Hull, R.D. (2014). Therapeutic use of warfarin and other vitamin K antagonists. Retrieved September 29, 2014 from: <http://www.uptodate.com/contents/therapeutic-use-of-warfarin-and-other-vitamin-k-antagonists?source=machineLearning&search=warfarin&selectedTitle=5~150&sectionRank=1&anchor=H21#H21>

Warr, D. (2014). Prognostic factors for chemotherapy induced nausea and vomiting. *European Journal of Pharmacology*, 722(1), 192-196. doi:<http://dx.doi.org/10.1016/j.ejphar.2013.10.015>

Wickham, R. Nausea and Vomiting. Yarbro CH, Frogge MH, Goodman M, editors. *Cancer Symptom Management*. 3rd ed. Sudbury, Massachusetts: Jones and Bartlett Publishers; 2004. p. 187-214.

## Oral Mucositis

Beck, S. Mucositis. In: Yarbro CH, Frogge MH, Goodman M, editors. *Cancer Symptom Management*. 3<sup>rd</sup> ed. Sudbury, Massachusetts: Jones and Bartlett Publishers; 2004. p 276–92.

Broadfield, L., & Hamilton, J. Best Practice Guidelines for the management of oral complications from cancer therapy. Full Version. Supportive Care Cancer Site Team. Cancer Care Nova Scotia; 2006: p. 1- 83.

Broadfield, L., & Hamilton, J. Best Practice Guidelines for the management of oral complications from cancer therapy. Quick Reference Version. Supportive Care Cancer Site Team. Cancer Care Nova Scotia; 2006: p. 1-18.

- Brown, C.G. Where do we go from here? The evidence based approach to the treatment of oral mucositis. *Oncology Supportive Care Quarterly*; 3(2): 11-17.
- Brown, C.G., & Wingard, J. (2004). Clinical consequences of oral mucositis. *Seminars in Oncology Nursing*, 20(1), 16–21.
- Bruce, S.D. (2004). Pain management issues and strategies in oral mucositis. *Oncology Supportive Care Quarterly*, 3(2), 18-27.
- Bruce, S.D. (2004). Radiation – induced xerostomia: How dry is your patient? *Clinical Journal of Oncology Nursing*, 8(1), 61–67.
- Canadian Association of Nurses in Oncology/ Association canadienne des infirmières en oncologie (CANO/ACIO). Practice Standards and Competencies for the Specialized Oncology Nurse. 2006: 1-47.
- Cancer Care Ontario. (2012). Mucositis in Adults with Cancer: Screening and Assessment. Retrieved March 27, 2018 from: <https://www.cancercareontario.ca/en/symptom-management/3156>
- Cancer Care Ontario. (2012). Symptom Management Guide-to-Practice: Oral Care. Retrieved March 27, 2018 from: <https://www.cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=58189>
- Caplinger, J., Royse, M., & Martens, J., (2010). Implementation of an Oral Care Protocol to Promote Early Detection and Management of Stomatitis. *Clinical Journal of Oncology Nursing*, 14(6), 799-802. doi: 10.1188/10.CJON.799-802.
- Cawley, M.M., & Benson, L.M. (2005). Current trends in managing oral mucositis. *Clinical Journal of Oncology Nursing*, 9(5), 584–592.
- Eilers, J., & Epstein, J.B. (2004). Assessment and measurement of oral mucositis. *Seminars in Oncology Nursing*, 20(1), 22-29.
- Eilers, J., & Million, R., (2011). Clinical update: Prevention and management of oral mucositis in patients with cancer. *Seminars in Oncology Nursing*, 27(4). P. e1-e16. doi: 10.1016/j.soncn.2011.08.001
- Eilers J, Million R. Prevention and management of oral mucositis in patients with cancer. *Seminars in Oncology Nursing*. 2007 Aug; 23(3): 201–212.
- Eilers, J. (2004). Nursing interventions and supportive care for the prevention and treatment of oral mucositis associated with cancer treatment. *Oncology Nursing Forum*, 31(4 Suppl), S13–S23.
- Epstein, J.B., & Schubert, M.M. (2004). Managing pain in mucositis. *Seminars in Oncology Nursing*, 20(1), 30–37.
- Fulton, J.S., Middleton, G.J., & McPhail, J.T. (2002). Management of oral complications. *Seminars in Oncology Nursing*, 18(1):28-35.
- Harris, D.J., Eilers, J., Harriman, A., Cashavelly, B.J., & Maxwell, C. (2008). Putting evidence into practice: Evidence-based Interventions for the Management of Oral Mucositis. *Clinical Journal of Oncology Nursing*, 12(1), 141-152. doi: 10.1188/08.CJON.141-152.
- Harris, D.J., & Knobf, M.T. (2004). Assessing and managing chemotherapy – induced mucositis pain. *Clinical Journal of Oncology Nursing*, 8(6), 622–628.
- International Society of Oral Oncology. (2016). How to Care for Yourself Before Head and Neck Radiation. Available from: [https://www.mascc.org/assets/StudyGroups/oralcare/en\\_head\\_neck\\_beforeraidiation.pdf](https://www.mascc.org/assets/StudyGroups/oralcare/en_head_neck_beforeraidiation.pdf)

International Society of Oral Oncology. (2016). How to Care for Yourself During Head and Neck Radiation. Available from: [https://www.mascc.org/assets/StudyGroups/oralcare/en\\_head\\_neck\\_duringradiation.pdf](https://www.mascc.org/assets/StudyGroups/oralcare/en_head_neck_duringradiation.pdf)

International Society of Oral Oncology. (2016). How to Care for Yourself After Head and Neck Radiation. Available from: [https://www.mascc.org/assets/StudyGroups/oralcare/en\\_head\\_neck\\_fterradiation.pdf](https://www.mascc.org/assets/StudyGroups/oralcare/en_head_neck_fterradiation.pdf)

Joanna Briggs Institute. Prevention and treatment of oral mucositis in cancer patients. Evidence Based Practice Information Sheets for Health Professionals (ISSN 1329 – 1874). 1998; 2(3): 1–5.

Karagozoglu, S., & Ulusoy, M.F. (2005). Chemotherapy: The effect of oral cryotherapy on the development of oral mucositis. *Journal of Clinical Nursing*, 14, 754-765.

Keefe, D.M., Schubert, M.M., Elting, L.S., Sonis, S.T., Epstein, J.B., Raber-Durlacher, J.E., Migliorati, C. A., McQuire, D.B., Hutchins, R.D., & Peterson, D. E. (2007). Updated Clinical practice Guidelines for the Prevention and Treatment of Mucositis. *American Cancer Society*.p. 820-831. doi: 10.1002/cncr.22484

Lalla, R.V., & Peterson, D.E. (2006). Treatment of mucositis, including new medications. *The Cancer Journal*, 12(5), 348–354.

Maher, K. Xerostomia. In: Yarbro CH, Frogge MH, Goodman M, editors. *Cancer Symptom Management*. 3<sup>rd</sup> ed. Sudbury, Massachusetts: Jones and Bartlett Publishers; 2004. p. 215-229.

McGuire, D.B., Johson, J., & Migliorati, C. (2006). Promulgation of guidelines for mucositis management: Educating health care professionals and patients. *Support Cancer Care*, 14, 548–557.

McGuire, D.B., Correa, M.E.P., Johson, J., & Wienandts, P. (2006). The role of basic oral care and good clinical practice Principles in the management of oral mucositis. *Support Care Cancer*, 14, 541-547.

McGuire, D.B., Rubenstein, E.B., & Peterson, D.E. (2004). Evidence-based guidelines for managing mucositis. *Seminars in Oncology Nursing*. 20(1), 59-66.

Miller, M., & Kearney, N. (2001). Oral care for patients with cancer: A review of the literature. *Cancer Nursing*, 24(1), 241–254.

National Cancer Institute, US National Institute of Health. (2016). Oral complications of chemotherapy and head/neck radiation (PDQ®) – Health Professional Version. Available from: <https://www.cancer.gov/about-cancer/treatment/side-effects/mouth-throat/oral-complications-hp-pdq>

National Institute of Health & National Cancer Institute (2018). Mouth and Throat Problems during Cancer Treatment. Available from: <https://www.cancer.gov/about-cancer/treatment/side-effects/mouth-throat>

National Institute of Health & National Cancer Institute (2010). Common Terminology Criteria for Adverse Events. Available from: [http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE\\_4.03\\_2010-06-14\\_QuickReference\\_8.5x11.pdf](http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf)

National Oncology Alliance. Oral Mucositis. NOA Treatment Guidelines. 2007; 1:1-3. Available from: [http://guidelines.noainc.com/documents/Guidelines/Mucositis\\_Guideline.pdf](http://guidelines.noainc.com/documents/Guidelines/Mucositis_Guideline.pdf)

National Oncology Alliance. Xerostomia. NOA Treatment Guidelines. 2006; 1:1-3. Available from: [http://guidelines.noainc.com/documents/Guidelines/Xerostomia\\_Guideline.pdf](http://guidelines.noainc.com/documents/Guidelines/Xerostomia_Guideline.pdf)

Oncology Nursing Society. (2011). Clinical practice references: Oral mucositis. Retrieved March 15, 2013 from: <http://www.ons.org/ClinicalResources/OralMucositis>

Peterson, D.E. (2006). New strategies for management of oral mucositis in cancer patients. *The Journal of*



*Supportive Care*, 4(2 Suppl 1), S9-S14.

Peterson, D.E., Beck, S.L., & Keefe, D.M.K. (2004). Novel therapies. *Seminars in Oncology Nursing*, 20(1), 53-58.

Rubenstein, E.B., Peterson, D.E., Schubert, M., Keefe, D., McGuire, D., Epstein, J., et al. (2004). Clinical practice Guidelines for the prevention and treatment of cancer therapy – induced oral and gastrointestinal mucositis. *Cancer*, 100(9 Supplement), S2026–S2046.

Silverman, S. (2007). Diagnosis and management of oral mucositis. *The Journal of Supportive Care*, 5 (2 Suppl 1), S13–S21.

Sonis, S.T., Elting, L.S., Keefe, D., Peterson, D.E., Schubert, M., Hauer- Jensen, M., et al. (2004). Perspectives on cancer therapy – induced mucosal injury. *Cancer*, 100(9), 1995–2025.

Sonis, S.T. (2004). Oral mucositis in cancer therapy. *The Journal of Supportive Care*, 2(3), 3–8.

Stone, R., Fliedner, M.C., Smiet, A.C.M. (2005). Management of oral mucositis in patients with cancer. *European Journal of Oncology Nursing*, S24-S32.

Van Gerpen, R. (2005). An overview of oral mucositis. *Oncology Supportive Care Quarterly*, 3(2), 4-10.

Worthington, H.V., Clarkson, J.E., Eden, O.B. (2007). Interventions for treating oral mucositis for patients with cancer receiving treatment. The Cochrane Database of Systematic Reviews. Wiley Publishers; 2007 Issue 1: 1-32.

## Pain

Agency for Health Care Policy and Research. Clinical Practice Guideline. Number 9. Management of Cancer Pain. [cited from: 2007, June.] Available from:  
<http://www.painresearch.utah.edu/cancerpain/guidelineF.html/>

American Pain Society. Guideline for the management of cancer pain in adults and children. Illinois; 2005.

BC Centre for Palliative Care (2017). *Pain Assessment in Advanced Dementia (PAINAD) Scale*. Retrieved from <http://bcbpsd.ca/docs/part-1/Final%20Provincial%20PAINAD%20Scale.pdf>

Boulanger, A., Gallagher, R., Gillen, M., Goldman, B., Pelosa, P., & Thompson, E. Managing pain: The Canadian healthcare professional's journal. Toronto: Healthcare & Financial Publishing: 2001.

Canadian Association of Nurses in Oncology/ Association canadienne des infirmieres en oncologie. CANO Cancer Pain Management Manual (2004).

Canadian Cancer Society, (n.d.). *Side effects of hormonal therapy*. Retrieved from:  
<http://www.cancer.ca/en/cancer-information/diagnosis-and-treatment/chemotherapy-and-other-drug-therapies/hormonal-therapy/side-effects-of-hormonal-therapy/?region=on>

Cancer Care Ontario, Nursing Professional Advisory Committee. Pain guideline. Telephone Nursing Practice and Symptom Management Guidelines. 2004, Apr 5 [cited 2007 June 10]:25-26 Available from: <http://www.cancercare.on.ca/documents/NursingTelephonePracticeGuidelines.pdf>

Cancer Care Ontario. Symptom Management Guides-to-practice: Pain. 2010. Available from:  
<https://www.cancercare.on.ca/toolbox/symptools/>

- Candido, K. D., Kusper, T. M., & Knezevic, N. N. (2017). New cancer pain treatment options. *Current Pain and Headache Reports*, 21(2), 12. doi:10.1007/s11916-017-0613-0
- Current Pain and Headache Reports*, 21(2), 12. doi:10.1007/s11916-017-0613-0
- Clarysse, A. (1985). Hormone-induced tumor flare. *European Journal of Cancer and Clinical Oncology*, 21(5), 545-547.
- Davies, A. N. (2014). Breakthrough cancer pain. *Current Pain and Headache Reports*, 18(6), 420. doi:10.1007/s11916-014-0420-9
- Dine, J., Gordon, R., Shames, Y., Kasler, M.K., & Barton-Burke, M. (2017). Immune checkpoint inhibitors: an innovation in immunotherapy for the treatment and management of patients with cancer. *Asia-Pacific Journal of Oncology Nursing*, 4(2), 127-135. doi:10.4103/apjon.apjon\_4\_17
- Doyle, D., Hanks, G., Cherny, N., Calman, K. Oxford textbook of palliative medicine. 3<sup>rd</sup> ed. New York.: Oxford University Press: 2005.
- Ferrell, B. A. (2000). Pain Assessment. In: Osterweil, D., Brummel, B., Smith, K., & Beck, J. C. (Eds.). *Comprehensive Geriatric Assessment*. New York: McGraw Hill.
- Fisch, M., & Burton, A. Cancer pain management. New York: The McGraw-Hill Companies, Inc.: 2007
- Fraserhealth Palliative Care Program. Pain. Hospice Palliative Care Program Symptom Guidelines. 2006, Dec 5; [cited 2007, June]: Available from: <http://www.fraserhealth.ca/NR/rdonlyres/exzxwiauml64dmmt66x24j3yilkr4uyccewx2ligebtett5eublw7o23jui23jindub4vynblxqtic/16FHSymptomGuidelinesOpioid.pdf/>
- Gaertner, J. & Schiessl, C. (2013). Cancer pain management: what's new? *Current Pain and Headache Reports*, 17(4), 328. doi:10.1007/s11916-013-0328-9
- Jamison, R. N., & Mao, J. (2015). Opioid Analgesics. *Mayo Clinic Proceedings*, 90(7), 957-968. doi:10.1016/j.mayocp.2015.04.010
- Liu, W. C., Zheng, Z. X., Tan, K. H., & Meredith, G. J. (2017). Multidimensional treatment of cancer pain. *Current Oncology Reports*, 19(2), 10 doi:10.1007/s11912-017-0570-0
- Mercadante, S., Bruera, E. (2016). Opioid switching in cancer pain: from the beginning to nowadays. *Critical Reviews in Oncology/Hematology*, 99, 241-248. doi:10.1016/j.critrevonc.2015.12.011
- Middleton, C. (2003). Understanding the physiological effects of unrelieved pain. *Nursing Times*, 99(37), 28-31.
- Ministry of Health. Singapore. Cancer Pain. Clinical Practice Guidelines 2003. Available from: <http://www.moh.gov.sg/mohcorp/publications.aspx?id=16376/>
- Moudi, M., Go, R., Yong Seok Yien, C., & Nazre, M. (2013). Vinca Alkaloids, *International Journal of Preventative Medicine*, 4(11), 1231-1235.
- National Cancer Institute. US National Institute of Health. Pain. (PDQ®) – Health Professional Version. Available from: <http://www.cancer.gov/cancertopics/pdq/supportivecare/pain/HealthProfessional/page1/AllPages>
- National Comprehensive Cancer Network. NCCN. Clinical Practice Guidelines in Oncology. Adult Cancer Pain. V.1. 2012. Available from: [http://www.nccn.org/professionals/physician\\_gls/pdf/antiemesis.pdf](http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf)
- National Health Services. The Management of Pain in Patients with Cancer. Best Practice Statement. April 2004.[cited from 2007, June] Available from: <http://www.nhshealthquality.org/nhsqis/1368.html/>

National Institute of Health & National Cancer Institute (2010). Common Terminology Criteria for Adverse Events. Available from : [http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE\\_4.03\\_2010-06-14\\_QuickReference\\_8.5x11.pdf](http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf)

National Oncology Alliance. Pain Management. NOA Treatment Guidelines. 2006; 1-3. Available from: [http://guidelines.noainc.com/documents/Guidelines/Pain\\_Management\\_Guideline.pdf](http://guidelines.noainc.com/documents/Guidelines/Pain_Management_Guideline.pdf)

Oncology Nursing Society. Pain Management Guideline. [cited from 2007, June] Available from: <http://www.ons.org/outcomes/Clinical/pdf/PainOverview.pdf/>

Paice, J.A. Pain. In: Yarbro CH, Frogge MH, Goodman M, editors. Cancer Symptom Management. 3rd ed. Sudbury, Massachusetts: Jones and Bartlett Publishers; 2004. p. 77-96.

Portenoy, R.K., & Dhingra, L.K. Overview of cancer pain syndromes. Available from:

[http://www.uptodate.com/contents/overview-of-cancer-pain-syndromes?detectedLanguage=en&source=search\\_result&search=overview+of+cancer+pain+syndromes&selectedTitle=1%7E150&provider=noProvider](http://www.uptodate.com/contents/overview-of-cancer-pain-syndromes?detectedLanguage=en&source=search_result&search=overview+of+cancer+pain+syndromes&selectedTitle=1%7E150&provider=noProvider)

Portenoy, R.K., Ahmed, E., & Keilson, Y.Y. Cancer pain management: Adjuvant analgesics (co-analgesics).

Available from: [http://www.uptodate.com/contents/cancer-pain-management-adjuvant-analgesics-coanalgesics?detectedLanguage=en&source=search\\_result&search=cancer+pain+management&selectedTitle=2%7E80&provider=noProvider](http://www.uptodate.com/contents/cancer-pain-management-adjuvant-analgesics-coanalgesics?detectedLanguage=en&source=search_result&search=cancer+pain+management&selectedTitle=2%7E80&provider=noProvider)

Taleb, A.B. (2017). Tumor flare reaction in cancer treatments: a systematic review. *Journal of Clinical Oncology*, 35(15), e18256. doi:10.1200/JCO.2017.35.15\_suppl.e18258

Tatrow, K. & Montgomery, G. H. (2006). Cognitive behavioural therapy techniques for distress and pain in breast cancer patients: a meta-analysis. *Journal of Behavioural Medicine*, 29(1), 17-27. doi:10.1007/s10865-005-9036-1

Tennant, F. (2013). The physiologic effects of pain on the endocrine system. *Pain and Therapy*, 2(2), 75-86. doi:10.1007/s40122-013-0015

## Palmar Plantar Erythrodysesthesia (PPE)

Aigal, Z., Chapuis, N., Emile, G., Cessot, A et al. (2015) Risk factors for pegylated (liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters. Published online September 29, 2015 *Springer-Verlag* . Retrieved Jan. 21, 2019.

American Society of Clinical Oncology (ASCO) Retrieved online January 21, 2019.

<https://www.cancer.net/navigating-cancer-care/side-effects/skin-reactions-targeted-therapy-and-immunotherapy>

Baran, R., & Roujeau, J. (2002). New millennium, new nail problems. *Dermatologic Therapy*, 15, 64.

Bardia, A., Loprinzi, C. L., & Goetz, M. P. (2006). Hand-foot syndrome after dose-dense adjuvant chemotherapy for breast cancer: A case series. *Journal of Clinical Oncology*, 24(13),18e.

Berg, D. T. (2006). Capecitabine: A new adjuvant option for colorectal cancer. *Clinical Journal of Oncology Nursing*, 10(4), 479-486.

Bush, N. J., & Smith, L. H. (2001). Hand - foot syndrome. *Oncology Nursing Forum*, 28(10), 1519-1520.

Cancer Care Ontario - Professional Pharmacy Advisory Committee - Medication Information Sheets Working Group. (2007). *Patient info sheet - hand-foot syndrome*. Retrieved September, 2007, from <http://www.cancercare.on.ca/pdfmedicationinfo/Hand-foot%20Syndrome.pdf>

- Cancer Care Ontario Nursing Professional Advisory Committee Telephone Practice Working Group. (2005). *Telephone nursing practice and symptom management guideline; skin alteration guideline*. Retrieved August 7, 2007, from <http://www.cancercare.on.ca/documents/NursingTelephonePracticeGuidelines.pdf>
- Clark, M. (2008). Reader seeks clarification on hand-foot skin reaction. [Letter to the editor]. *Clinical Journal of Oncology Nursing*, 12 (3), 395.
- Degen, A., Alter, M., Schenck, F., Satzger, I., Volker, B., Kapp, A., & Gutzmer, R. (2010). The hand-foot-syndrome associated with medical tumor therapy- classification and management. *Journal of the German Society of Dermatology*. 8. 652-661. doi: 10.1111/j.1610-0387.2010.07449.x
- Drake, R. D., Lin, W. M., King, M., Farrar, D., Miller, D. S., & Coleman, R. L. (2004). Oral dexamethasone attenuates doxil-induced palmar-plantar erythro-dysesthesias in patients with recurrent gynecologic malignancies. *Gynecologic Oncology*, 94(2), 320.
- Facts & Comparisons 4.0. (2007). *Capecitabine*. Retrieved September, 2007, from <http://online.factsandcomparisons.com/MonoDisp.aspx?book=DFC&monoid=fandc-hcp10387&searched=CAPECITABINE>
- Facts & Comparisons 4.0. (2007). *Doxorubicin, hydrochloride liposomal*. Retrieved September, 2007, from <http://online.factsandcomparisons.com/monodisp.aspx?book=dfc&monoid=fandc-hcp10717&searched=liposomal%20doxorubicin>
- Goldman, A.L., & Braman, S.S. (1972). Isoniazid: A review with emphasis on adverse effects. *Chest*, 62(1), 71-77.
- Gressett, S.M., Stanford, B.L., & Hardwicke, F. (2006). Management of hand-foot syndrome induced by capecitabine. *Journal of Oncology Pharmacy Practice*, 12(3), 131.
- Hamilton Regional Cancer Centre - Patient Education Committee. (2004). *Medication info sheet – capecitabine*.
- Hoffmann-La Roche Limited. *Xeloda®*.
- Jansman, F.G.A., Sleijfer, D.T., de Graaf, J.C., Coenen, J.L.L.M., & Brouwers, J. R. B. J. (2001). Management of chemotherapy- induced adverse effects in the treatment of colorectal cancer. *Drug Safety*, 24(5), 353-367.
- Jung, S., et al. (2017) Prevention of palmar plantar erythrodysesthesia in patients treated with pegylated liposomal doxorubicin (Caelyx) ® . Supportive Care Cancer. Published online 26 June 2017 *Springer-Verlag* 3545-3549
- Lacouture, M., & McLellan, B. (2019) Hand-foot skin reaction induced by multitargeted tyrosine kinase inhibitors. *Up-to-date*-retrieved on January 9, 2019
- Lee, S., Lee, S., Chun, Y., Kim, M., Chang, H., Kim, T., et al. (2007). Pyridoxine is not effective for the prevention of hand foot syndrome (HFS) associated with capecitabine therapy: Results of a randomized double-blind placebo-controlled study. *Journal of Clinical Oncology*, 25(18S).
- Leo, S., Tatulli, C., Taveri, R., Campanella, G. A., Carrieri, G., & Colucci, G. (1994). Dermatological toxicity from chemotherapy containing 5-fluorouracil. *Journal of Chemotherapy*, 6 (6), 423.
- Lichtman, S.M., Wildiers, H., Chatelut, E., Steer, C., Budman, D., Morrison, V.A., et al. (2007). International society of geriatric oncology chemotherapy taskforce: Evaluation of chemotherapy in older patients - an analysis of the medical literature. *Journal of Clinical Oncology*, 25 (14), 1832.
- Lin, E. H. (2002). COX-2 inhibitor may boost capecitabine response. *Oncology News*, 11 (7).

- Lin, E.H., Morris, J. S., & Ayers, G.D. (2002). Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. *Oncology*, 16( 12 Supplement), 31.
- Lipworth, A., Robert, C., & Zhum, A. (2009). Hand-foot syndrome reaction, (Hand-foot skin reaction, palmar plantar erythrodysesthesia): Focus on sorafenib and sunitinib. *Oncology*, 77, 257-271.
- Lopez, A.M., Wallace, L., Dorr, R.T., Koff, M., Hersh, E.M., & Alberts, D.S. (1999). Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. *Cancer Chemotherapy and Pharmacology*, 44 (4), 303.
- Lorusso, D., Di Stefano, A., Carone, V., Fagotti, A., Pisconti, S., & Scambia, G. (2007). Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot syndrome'). *Annals of Oncology*, 18 (7), 1159-64.
- Mangili, G., Gentile, C., Rabaiotti, E., Pella, F., Petrone, M., Zanetto, F., et al. (2006). The role of regional cooling on prevention of palmar-plantar erythrodysesthesia in patients treated with pegylated liposomal doxorubicin. *International Journal of Gynecological Cancer*, 16 (Supplement 3), 790.
- Marse, H., Van Cutsem, E., Grothey, A., & Valverde, S. (2004). Management of adverse events and other practical considerations in patients receiving capecitabine (xeloda). *European Journal of Oncology Nursing*, 8, S16.
- Molpus, K. L., Anderson, L. B., Craig, C. L., & Puleo, J. G. (2004). The effect of regional cooling on toxicity associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma. *Gynecologic Oncology*, 93 (2), 513.
- Moore, S. (2007). Facilitating oral chemotherapy treatment and compliance through patient/family - focused education. *Cancer Nursing*, 30 (2), 112-122.
- Nagore, E., Insa, A., & Onofre, S. (2000). Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. *American Journal of Clinical Dermatology*, 1 (4), 225.
- National Institute of Health & National Cancer Institute (2010). Common Terminology Criteria for Adverse Events. Available from : [http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE\\_4.03\\_2010-06-14\\_QuickReference\\_8.5x11.pdf](http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf)
- Payne, A.S., Harris, J.E. & Savarese, Diane M. F. (2007). *Cutaneous complications of chemotherapy*. Retrieved January 23, 2008, from [http://www.utdol.com/utd/content/topic.do?topicKey=genl\\_onc/11928&selectedTitle=1~150&source=search\\_result](http://www.utdol.com/utd/content/topic.do?topicKey=genl_onc/11928&selectedTitle=1~150&source=search_result)
- Payne, AS., & Savarese, D. (2019) Cutaneous side effects of conventional chemotherapy agents. *Up-to-date*-retrieved on January 9, 2019.
- Pendharkar, D., & Goyal, H. (2004). Novel & effective management of capecitabine induced hand foot syndrome. *Journal of Clinical Oncology*, 22 (14S), 8105.
- Peuvrel, L., & Dreno, B. (2014) Dermatological toxicity associated with targeted therapies in cancer: optimal management. *American Journal of Clinical Dermatology* volume15: 425-444.
- Popescu, R. A., Norman, A., Ross, P. J., Parikh, B., & Cunningham, D. (1999). Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. *Journal of Clinical Oncology*, 17 (8), 2412.
- Qiao, J., & Fang, H.(2012) Hand-foot syndrome related to chemotherapy. *Canadian Medical Association Journal*. (2012) 18 (c15)

- Rosen, A., Amitay-Laish, I., & Lacouture, M. (2014). Management algorithms for dermatologic adverse events. *Dermatologic Principles and Practice in Oncology: Conditions of the Skin, Hair, and Nails in Cancer Patients*, first edition 367-383
- Saif, M. W., & Elfiky, A. A. (2007). Identifying and treating fluoropyrimidine-associated hand-and-foot syndrome in white and non-white patients. *Supportive Oncology*, 5 (7), 337.
- Samel, A. D. (2007). *Drug eruptions*. Retrieved January 23, 2008, from [http://www.utdol.com/utd/content/topic.do?topicKey=pri\\_derm/5243&selectedTitle=1~53&source=search\\_result](http://www.utdol.com/utd/content/topic.do?topicKey=pri_derm/5243&selectedTitle=1~53&source=search_result)
- Scheithauer, W., & Blum, J. (2004). Coming to grips with hand-foot syndrome - insights from clinical trials evaluating capecitabine. *Oncology*, 18 (9).
- Schering Canada Inc. (2003). *Caelyx® - pegylated liposomal doxorubicin hydrochloride for injection: Guide to administration in metastatic breast cancer and advanced ovarian cancer*.
- Scott Hamilton CARES Initiative. (2005). *Side effects - symptoms & solutions hand-foot syndrome*. Retrieved January 23, 2008, from [http://www.chemocare.com/managing/handfoot\\_syndrome.asp](http://www.chemocare.com/managing/handfoot_syndrome.asp)
- Scotte, F., Tournani, J., Banu, E., Peyromaure, M., Levy, E., Marsan, S., et al. (2005). Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. *Journal of Clinical Oncology*, 23 (19), 4424.
- Shi, V., Levy, L., & Choi, J. Cutaneous manifestations of nontargeted and targeted chemotherapies (2016) *Seminars in Oncology*
- Stubblefield, M. D., Custodio, C. M., & Kaufmann, Petra' Dickler, Maura N. (2006). Small-fiber neuropathy associated with capecitabine (xeloda®)-induced hand-foot syndrome: A case report. *Clinical Neuromuscular Disease*, 7 (3), 128.
- Swenson, K., & Bell, E. (2010). Hand-foot syndrome related to liposomal doxorubicin. *Oncology Nursing Forum* 37 (2), 137–139.
- University of Florida Shands Cancer Center. *Hand-foot syndrome (palmar-plantar erythrodysesthesia)*. Retrieved January 23, 2008, from <http://ufsc.c.ufl.edu/Patient/content.aspx?section=cancertreatment&id=23169>
- UpToDate. *Capecitabine: Drug information*. Retrieved January 23, 2008, from [http://www.utdol.com/utd/content/topic.do?topicKey=drug\\_a\\_k/197964&view=print](http://www.utdol.com/utd/content/topic.do?topicKey=drug_a_k/197964&view=print)
- UpToDate. *Cytarabine: Drug information*. Retrieved January 23, 2008, from [http://www.utdol.com/utd/content/topic.do?topicKey=drug\\_a\\_k/69863&view=print](http://www.utdol.com/utd/content/topic.do?topicKey=drug_a_k/69863&view=print)
- UpToDate. *Docetaxel: Drug information*. Retrieved January 23, 2008, from [http://www.utdol.com/utd/content/topic.do?topicKey=drug\\_a\\_k/85805&view=print](http://www.utdol.com/utd/content/topic.do?topicKey=drug_a_k/85805&view=print)
- UpToDate. *Etoposide: Drug information*. Retrieved January 23, 2008, from [http://www.utdol.com/utd/content/topic.do?topicKey=drug\\_a\\_k/101030&view=print](http://www.utdol.com/utd/content/topic.do?topicKey=drug_a_k/101030&view=print)
- UpToDate. *Fluorouracil: Drug information*. Retrieved January 23, 2008, from [http://www.utdol.com/utd/content/topic.do?topicKey=drug\\_a\\_k/108832&view=print](http://www.utdol.com/utd/content/topic.do?topicKey=drug_a_k/108832&view=print)
- UpToDate. *Lapatinib: Drug information*. Retrieved January 23, 2008, from [http://www.utdol.com/utd/content/topic.do?topicKey=drug\\_l\\_z/38019&view=print](http://www.utdol.com/utd/content/topic.do?topicKey=drug_l_z/38019&view=print)
- UpToDate. *Liposomal doxorubicin: Drug information*. Retrieved January 23, 2008, from [http://www.utdol.com/utd/content/topic.do?topicKey=drug\\_l\\_z/48245&view=print](http://www.utdol.com/utd/content/topic.do?topicKey=drug_l_z/48245&view=print)

UpToDate. *Sorafenib: Drug information*. Retrieved January 23, 2008, from [http://www.utdol.com/utd/content/topic.do?topicKey=drug\\_l\\_z/82001&view=print](http://www.utdol.com/utd/content/topic.do?topicKey=drug_l_z/82001&view=print)

UpToDate. *Sunitinib: Drug information*. Retrieved January 23, 2008, from Viele, C. S. (2007). Managing oral chemotherapy: The healthcare practitioner's role. *American Journal of Health-System Pharmacy. Advancing the Safe and Appropriate use of Oral Chemotherapy Agents*, 64 (9 Supplement 5), S25-S32.

Vukelja, J. S., Lombardo, F. A., James, W. D., & Weiss, R. B. (1989). Pyroxidine for the palmar-plantar erythrodysesthesia syndrome. *Annals of Internal Medicine*, 111(8; 8), 688-689.

Webster-Gandy, J. D., How, C., & Harrold, K. (2007). Palmar–plantar erythrodysesthesia (PPE): A literature review with commentary on experience in a cancer centre. *European Journal of Oncology Nursing*, 11(3), 238-246.

Wilkes, G. M., & Doyle, D. (2005). Palmar-plantar erythrodysesthesia. *Clinical Journal of Oncology Nursing*, 9(1), 103-106.

Yucel, I., & Guzin, G. (2007). Topical henna for capecitabine induced hand-foot syndrome. *Investigational New Drugs*, doi:10.1007/s10637-007-9082-3.

## Peripheral Neuropathy (Chemotherapy-Induced)

Armstrong, T., Almadrones, L., & Gilbert, M.R. (2005). Chemotherapy-induced peripheral neuropathy. *Oncology Nursing Forum*, 32(2), 305-311.

Bakitas, M.A. (2007). Background noise. The experience of chemotherapy-induced peripheral neuropathy. *Nursing Research*. 56(5), 323-331.

Brami, C., Bao, T., & Deng, G. (2016). Natural products and complementary therapies for chemotherapy-induced peripheral neuropathy: a systematic review, *Crit. Rev. Oncol. Hematol.*, 98, pp. 325-334

Dunlap, B., & Paice, J.A. (2006). Chemotherapy-induced peripheral neuropathy: A need for standardization in measurement. *The Journal of Supportive Oncology*. 4(8), 398-399.

Grisold, W., Cavaletti, G., & Windebank, A. J. (2012). Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. *Neuro-Oncology*, 14(Suppl 4), iv45–iv54.  
<http://doi.org/10.1093/neuonc/nos203>

Hanai, A., Ishiguro, H., Sozu, T., et al. (2018). Effects of cryotherapy on objective and subjective symptoms of paclitaxel-induced neuropathy: Prospective self-controlled trial. *Junior National Cancer Institute*, 110 (2), pp.141-148. <https://doi.org/10.3389/fonc.2016.00274>

Kayley, T.J., & DeAngelis, L.M. (2009). Therapy of chemotherapy-induced peripheral neuropathy. *British Journal of Haematology*, 145, 3-14.

Lee, E.Q., & Wen, P.Y. (2013). Neurologic complications of platinum-based chemotherapy. Up-to-date. Retrieved July 20, 2013 from: [http://www.uptodate.com/contents/neurologic-complications-of-platinum-based-chemotherapy?detectedLanguage=en&source=search\\_result&search=Neurologic+complications+of+platinum-based+chemotherapy&selectedTitle=1%7E150&provider=noProvider](http://www.uptodate.com/contents/neurologic-complications-of-platinum-based-chemotherapy?detectedLanguage=en&source=search_result&search=Neurologic+complications+of+platinum-based+chemotherapy&selectedTitle=1%7E150&provider=noProvider)

Lee, E.Q., & Wen, P.Y. (2013). Neurologic complications of non-platinum cancer chemotherapy. Up-to-date. Retrieved July 20, 2013 from: <http://www.uptodate.com/contents/neurologic-complications-of-non-platinum-cancer->

[chemotherapy?detectedLanguage=en&source=search\\_result&search=Neurologic+complications+of+platinum-based+chemotherapy&selectedTitle=2%7E150&provider=noProvider](https://www.uptodate.com/contents/prevention-and-treatment-of-chemotherapy-induced-peripheral-neuropathy?search=Drug-induced%20neuropathies&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2)

Loprinzi, C. (2018). Prevention and treatment of chemotherapy-induced peripheral neuropathy. Up-to-date. Retrieved August 28, 2018 from: [https://www.uptodate.com/contents/prevention-and-treatment-of-chemotherapy-induced-peripheral-neuropathy?search=Drug-induced%20neuropathies&source=search\\_result&selectedTitle=2~150&usage\\_type=default&display\\_rank=2](https://www.uptodate.com/contents/prevention-and-treatment-of-chemotherapy-induced-peripheral-neuropathy?search=Drug-induced%20neuropathies&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2)

Marrs, J., & Newton, S. (2003). Updating your peripheral neuropathy “know-how”. *Clinical Journal of Oncology Nursing*, 7(3), 299-303.

Memorial Sloan Kettering Cancer Center. (2017). Carpal tunnel syndrome. Patient & Caregiver Education. Retrieved August 28, 2018 from <https://www.mskcc.org/cancer-care/patient-education/carpal-tunnel-syndrome>

Nagle, S., Stelec, L., Loren, A., Landsburg, D., Nasta, S., Mato, A. (2017). Brentuximab-induced peripheral neuropathy: Risk factors and patient experiences. *Journal of Clinical Oncology*. 35 (5), pp. 120-120. DOI: 10.1200/JCO.2017.35.5\_suppl.120

National Institute of Health & National Cancer Institute (2010). Common Terminology Criteria for Adverse Events. Available from : [http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE\\_4.03\\_2010-06-14\\_QuickReference\\_8.5x11.pdf](http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf)

National Cancer Institute Cancer Therapy Evaluation Program. Peripheral Neuropathy. NCI Common Terminology Criteria for Adverse Events (version 3.0) 2006, August 09. [cited January 28, 2008]: 1–72. Available from: <http://ctep.cancer.gov>

Nishihori, T., Jaehyuc, C., DiGiovanna, M.P., Thomson, G., Kohler, P., McGum, J., & Chung, G. (2008). Carpal tunnel syndrome associated with the use of aromatase inhibitors in breast cancer. *Clinical Breast Cancer*, 8 (4), pp. 362-365. Retrieved August 28, 2018 from <https://www.sciencedirect.com/science/article/pii/S1526820911705316?via%3Dihub>

Oestreicher, P. (2007). Put evidence into practice to treat chemotherapy-induced peripheral neuropathy. Available from: <http://www.thefreelibrary.com/Put+evidence+into+practice+to+treat+Chemotherapy-induced+peripheral...-a0187773144>

Oncology Nursing Society. Measuring oncology nursing-sensitive outcomes: Evidence-based summary, peripheral neuropathy. Evidence – Based Practice Resource Area. [cited January 23, 2008]. Available from: <http://onsopcontent.ons.org/toolits/evidence/Clinical/summaries.html>

Oncology Nursing Society. Peripheral Neuropathy, definitions list. Evidence – Based Practice Resource Area. [cited January 23, 2008]. Available from: <http://onsopcontent.ons.org/toolits/evidence/Clinical/summaries.html>

Pachman, D.R., Barton, D.L., Watson, J.C., & Loprinzi, C.L. (2011). Chemotherapy-induced peripheral neuropathy: Prevention and treatment. *Clinical Pharmacology and Therapeutics*, 90(3), 377-386.

Paige, J.A. (2009). Clinical challenges: Chemotherapy-induced peripheral neuropathy. *Seminars in Oncology Nursing*, 25 (2, Suppl 1), S8-S19.

Prinsloo, S., Novy, D., Driver, L., Lyle, R., Ramondetta, L., Eng, C., ... Cohen, L. (2017). Randomized Controlled Trial of Neurofeedback on Chemotherapy-Induced Peripheral Neuropathy: A Pilot Study. *Cancer*, 123(11), 1989–1997. <http://doi.org/10.1002/cncr.30649>

Slade, J.H. (2005). Neurological toxicities associated with cancer chemotherapeutic agents. *US Pharmacist*, 4(Onc Suppl), 3-18.



- Sweeney, C.W. (2002). Understanding peripheral neuropathy in patients with cancer: Background and patient assessment. *Clinical Journal of Oncology Nursing*, 6(3),163-166.
- Spagnolo, F., Sestak, I., Howell, A., Forbes, J., & Cuzick, J. (2016). Anastrozole-induced carpal tunnel syndrome: Results from the international breast cancer intervention study II prevention trial. *Journal Of Clinical Oncology*. 34 (2). pp. 139-43. Retrieved August 28, 2018 from <http://ascopubs.org/doi/pdf/10.1200/JCO.2015.63.4972>
- Stone, J. B., & DeAngelis, L. M. (2016). Cancer Treatment-Induced Neurotoxicity: A Focus on Newer Treatments. *Nature Reviews. Clinical Oncology*, 13(2), 92–105. <http://doi.org/10.1038/nrclinonc.2015.152>
- Sundar, R., Bandla, A., Tan S.S., et al. (2017). Limb hypothermia for preventing paclitaxel-induced peripheral neuropathy in breast cancer patients: A pilot study. *Front Oncol* 2016; 274 (6), pp.1-10 <https://doi.org/10.1093/jnci/djx178>
- Verstappen, C.C.P., Heimans, J.J., Hoekman, K., & Postma, T.J. (2003). Neurotoxic complications of chemotherapy in patients with cancer: Clinical signs and optimal management. *Drugs*, 63(15), 1549-1563.
- Visovsky, C. (2003). Chemotherapy-induced peripheral neuropathy. *Cancer Investigation*, 21(3), 439-451.
- Visovsky, C., Collins, M.L., Hart, C., Abbott, L.I., & Aschenbrenner, J.A. Peripheral Neuropathy. Putting Evidence into Practice. Pittsburgh, PA, Oncology Nursing Society. 2007: 1-6 [cited December 20, 2007]. Available from: [www.ons.org/outcomes](http://www.ons.org/outcomes)
- Visovsky C, Collins ML, Hart C, Abbott LI, Aschenbrenner JA. Peripheral Neuropathy Detailed PEP Card. Putting Evidence into Practice. Pittsburgh, PA, Oncology Nursing Society. 2007: 1-6 [cited December 20, 2007]. Available from: [www.ons.org/outcomes](http://www.ons.org/outcomes)
- Visovsky, C., & Daly, B.L. (2004). Clinical evaluation and patterns of chemotherapy-induced peripheral neuropathy. *Journal of the American Academy of Nurse Practitioners*, 16(8), 353-359.
- Wickham, R. (2007). Chemotherapy-induced peripheral neuropathy: A review and implications for oncology nursing practice. *Clinical Journal of Oncology Nursing*, 11(3), 361–376.
- Wilkes, G.M. Peripheral Neuropathy. In: Yarbrow CH, Frogge MH, Goodman M, editors. *Cancer Symptom Management*. 3rd ed. Sudbury, Massachusetts: Jones and Bartlett Publishers; 2004. p. 333-358.
- Wilkes, G.M. (2007). Peripheral neuropathy related to chemotherapy. *Seminars in Oncology Nursing*, 23(3), 162-173.

## Radiation Dermatitis

- Aistars, J. (2006). The Validity of Skin Care Protocols Followed by Women with Breast Cancer Receiving External Radiation. *Clinical Journal of Oncology Nursing*, 10(4), 487-492.
- Archambeau, J., Pezner, R., & Wasserman, T. (1995). Pathophysiology of irradiated skin and breast. *International Journal of Radiation Oncology, Biology, & Physics*. 31, 1171-1185.
- Atiyeh, B., Ioannovich, J., Al-Amm., & El-Musa, K. (2002). Management of Acute and Chronic Open Wounds: The Importance of Moist Environment in Optimal Wound Healing. *Current Pharmaceutical Biotechnology*, 3, 179-195.
- Atiyeh, B., Costagliola, M., Hayek, S., & Dibo, S. (2007). Effect of silver on burn wound infection control and healing: review of the literature. *Burns*. 33 (2), 139-148.

- Babin, E., Sigston, E., Hitier, M., Dehesdin, D., Marie, J., & Choussy, O. (2008). Quality of life in head and neck cancer patients: predictive factors, functional and psychosocial outcome. *European Archives of Oto-Rhino-Laryngology*. 265, 265-270.
- Bentzen, S.M., & Overgaard, J. (1994). Patient to patient variability in the expression of radiation induced normal tissue injury. *Seminars in Radiation Oncology*, 4, 69-80.
- Bolderston, A. (2003). Skin Care Recommendations during Radiotherapy: A Survey of Canadian Practice. *The Canadian Journal of Medical Radiation Therapy*. 34(1), 3-11.
- Bolderston, A., Lloyd, N., Wong, L., & Robb-Blenderman, L. (2006). The prevention and management of acute skin reactions related to radiation therapy: a systematic review and practice guideline. *Supportive Care in Cancer*. 14, 802-817.
- Bostrom, A., Lindman, H., Swartling, C., Berne, B., & Bergh, J. (2001). Potent corticosteroid cream (mometasone furoate) significantly reduces acute radiation dermatitis: Results from a double blind, randomized study. *Radiotherapy and Oncology*. 59, 257-265.
- Burch, S., Oarjer, S., Vann, A., & Arazie, J. (1997). Measurements of 6MV X-Ray surface dose when topical agents are applied to external beam irradiation. *International Journal of Radiation Oncology, Biology and Physics*. 38(2), 447-451.
- Butcher, K., & Williamson, K. (2011). Management of erythema and skin preservation; advice for patients receiving radical radiotherapy to the breast: a systematic literature review. *Journal of Radiotherapy in Practice*, 1-11.
- Campbell, J., & Lane, C. (1996). Developing a skin-care protocol in radiotherapy. *Professional Nurse*, 12(2), 105-108.
- Cancer Care Ontario, (2005). The Prevention and Management of Acute Skin Reactions Related to Radiation Therapy: A Clinical Practice Guideline. <http://www.cancercare.on/cms/one.aspx>. (Date visited August 17, 2009.).
- Delaney, G., Fisher, R., Hook, C., & Barton, M. (1996). Sucralfate cream in the management of moist desquamation during radiotherapy. *Australasian Radiation*. 41, 270-275.
- Denham, J.W., Hamilton, C., Simpson, S., Ostwald, P., O'Brien, M., Kron, T., Joseph, D., & Dear, K. (1995). Factors influencing the degree of erythematous skin reactions in humans. *Radiation and Oncology*, 36,107-120.
- D'Haese, S., Bate, T., Claes, S., Boone, A., Vanvoorden, V., & Efficace, F. (2005). Management of skin reactions during radiotherapy: a study of nursing practice. *European Journal of Cancer Care*, 14, 28-42.
- Dorr, W. (2006). Skin and Other Reactions to Radiotherapy-Clinical Presentation and Radiobiology of Skin Reactions. In: *Controversies in the Treatment of Skin Neoplasias*. *Frontiers of Radiation Therapy Oncology*. 39, 96-101.
- Elliott, E., Wright, R., Swann, S., Nguyen-Tan, F., Takita, M., Bucci, M., Garden, A., Kim, H., Hug, E., Ryu, J., Greenberg, M., Saxton, J., Ang, K., & Berk, L. (2006). Phase III Trial of an Emulsion Containing Trolamine for the Prevention of Radiation Dermatitis in Patients with Advanced Squamous Cell Carcinoma of the Head and Neck. *Journal of Clinical Oncology*. 24(13), 2092-2097.
- Feight, D., Baney, T., Bruce, S., & McQuestion, M. (2011). Putting evidence into practice: Evidence-based interventions for radiation dermatitis. *Clinical Journal of Oncology Nursing*. 15(5), 481-492.  
doi:10.1188/11.CJON.481-492

- Fenig, E., Brenner, B., Katz, A., Sulkes, J., Lapidot, M., Schachter, J., Malik, H., Sulkes, A., & Gutman, H. (2001). Topical Biafine and Lipiderm for the prevention of radiation dermatitis: A randomized prospective trial. *Oncology Reports*, 8(2), 305-309.
- Fisher, J., Scott, C., Scarantino, C., Leveque, F., White, R., Rotman, M., Hodson, D., Meredith, R., Foote, R., Bachman, D., & Lee, N. (2000). Randomized Phase III Study comparing Best Supportive Care to Biafine as a Prophylactic Agent for Radiation Induced Skin Toxicity for Women Undergoing Breast Irradiation. *International Journal Radiation Oncology, Biology, & Physics*, 48(5), 1307-1310.
- Freedman, G., Anderson, P., Li, J., Eisenberg, M., Hanlon, A., Wang, L., & Nicolaou, N. (2006). Intensity Modulated Radiation Therapy (IMRT) Decreases Acute Skin Toxicity for Women Receiving Radiation for Breast Cancer. *American Journal of Clinical Oncology*, 29(1), 66-70.
- Halperin, E., George, S., Darr, D., Pinnell, S., & Gaspar, L. (1993). A double-blind, randomized, prospective trail to evaluate topical vitamin C solution for the prevention of radiation dermatitis. *International Journal of Radiation Oncology, Biology and Physics*, 26 (3), 413-416.
- Halperin, E., Perez, C., & Brady, L., ed., (2008). Principles and Practice of Radiation Oncology. 5<sup>th</sup> Edition. Philadelphia, Pennsylvania, USA: Lippincott Williams & Wilkins.
- Hannuksela, M., & Ellahham, S. (2001). Benefits and risks of sauna bathing. *American Journal of Medicine*, 10(2), 118-126.
- Harper, J., Franklin, L., Jenrette, J., & Aguero, E. (2004). Skin Toxicity During Breast Irradiation: Pathophysiology and Management. *Southern Medical Journal*, 97(10), 989-993.
- Hassey, K., & Rose, C. (1982). Altered Skin Integrity In Patients Receiving Radiation Therapy. *Oncology Nursing Forum*, 9 (4), 44-50.
- Heggie, S., Bryant, G., Tripcony, L., Keller, J., Rose, P., Glendenning, M., & Heath, J. (2002). A Phase III study on the efficacy of topical aloe vera gel on irradiation breast tissue. *Cancer Nursing*, 25 (6), 442-451.
- Hollinworth, H., & Mann, L. (2010). Managing acute skin reactions to radiotherapy treatment. *Nursing Standard*, 24(24), 53-64.
- Kedge, E, M. (2009). A systematic review to investigate the effectiveness and acceptability of interventions for moist desquamation in radiotherapy patients, *Radiography*, 15, 247-257.
- Kelsall, H., & Sim, M. (2001). Skin irritation in users of brominated pools. *International Journal of Environmental Health Research*, 11(1), 29-40.
- Khan, F.M. (2003). Physics of Radiation Therapy. 3<sup>rd</sup> Edition. Philadelphia, USA: Lippincott, Williams & Wilkins.
- Korinko, A., & Yurick, A. (1997). Maintaining Skin Integrity During Radiation Therapy. *American Journal of Nursing*, 97(2), 40-44.
- Kumar S, Juresic E, Barton M, Shafiq J. Management of skin toxicity during radiation therapy: a review of the evidence. *Journal of Medical Imaging and Radiation Oncology*. 2010;54:264–279.
- Lavery, B.A. (1995). Skin Care During Radiotherapy: A Survey of UK Practice. *Clinical Oncology*, 7, 184-187.
- Liguori, V., Guillemin, C., Pesce, G., Mirimanoff, R., & Bernier, J. (1997). Double-blind, randomized clinical study comparing hyaluronic acid cream to placebo in patients treated with radiotherapy. *Radiotherapy and Oncology*, 42, 155-161.

Lin, L., Que, J., Lin, L & Lin, F. (2006). Zinc Supplementation to Improve Mucositis and Dermatitis in Patients After Radiotherapy for Head and Neck Cancers: A Double Blind Randomized Study. *Radiation Oncology*, 65(3), 745-750.

National Institute of Health & National Cancer Institute (2010). Common Terminology Criteria for Adverse Events. Available from: [http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE\\_4.03\\_2010-06-14\\_QuickReference\\_8.5x11.pdf](http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf)

MacMillan, M., Wells, M., MacBride, M., Raab, G., Munro, A., & MacDougall, H. (2007). Randomized Comparison of Dry Dressings Versus Hydrogel in Management of Radiation Induced Moist Desquamation. *Radiation Oncology*, 68(3), 864-872.

Maddocks-Jennings, W., Wilkinson, J., & Shillington, D. (2005). Novel approaches to radiotherapy-induced skin reactions: A literature review. *Complementary Therapies in Clinical Practice*, 11, 224-231.

Maiche, A., Grohn, P., & Maki-Hokkonen, H. (1994). Effect of chamomile cream and almond ointment on acute radiation skin reaction. *Acta Oncologica*, 30, 395-396.

McNees, P. (2006). Skin and Wound Assessment and Care in Oncology. *Seminars in Oncology Nursing*, 22(3), 130-143.

McQuestion, M. (2011). Evidence-based skin care management in radiation therapy: Clinical update. *Seminars in Oncology Nursing*, 27(2), e1-e17. doi:10.1016/j.soncn.2011.02.009

McQuestion, M. (2006). Evidence-Based Skin Care Management in Radiation Therapy. *Seminars in Oncology Nursing*, 22 (3), 163-173.

National Health Service. (2004). Skincare of Patients Receiving Radiotherapy: Best Practice Statement. <http://www.nhshealthquality.org/nhsqis/files/20373%20NHS>. (Date visited September 12, 2008).

Naylor, W., & Mallett, J. (2001). Management of acute radiotherapy induced skin reactions: A literature review. *European Journal of Oncology Nursing*, 5(4), 221-233.

Noble-Adams, R. (1999). Radiation-induced reaction 1: An examination of the phenomenon. *British Journal of Nursing*. 8(17), 1134-1140.

Noronha, C., & Almelida, A. (2000). Local Burn Treatment-Topical Antimicrobial Agents. *Annals of Burns and Fire Disasters*, X111(4), 216-220.

Nouri, K. (2008). Skin Cancer. 1<sup>st</sup> Edition. USA: The McGraw Hill Companies Inc.

Olsen, D.L., Raub, W., Bradley, C., Johnson, M., Macias, J., Love, V., & Markoe, A. (2001). The effect of aloe vera gel/mild soap versus mild soap alone in preventing skin reactions in patients undergoing radiation therapy. *Oncology Nursing Forum*, 28(3), 543-547.

Otto, S., ed. (2001). Oncology Nursing. 4th Edition. St. Louis, Missouri: Mosby Inc.

Pignon, J.P. (2008). A Multicenter Randomized Trial of Breast Intensity-Modulated Radiation Therapy to Reduce Acute Radiation Dermatitis. *Journal of Clinical Oncology*, 26(13), 2085-2092.

Porock, D., Kristjanson, L., Nicoletti, S., Cameron, F., & Pedler, P. (1998). Predicting the Severity of Radiation Skin Reactions in Women with Breast Cancer. *Oncology Nursing Forum*, 25(6), 1019-1029.

Porock, D., Nikoletti, S., & Cameron, F. (2004). The Relationship between Factors That Impair Wound Healing and the Severity of Acute Radiation Skin and Mucosal Toxicities in Head and Neck Cancer. *Cancer Nursing*, 27(1), 71- 78.

- Primavera, G., Carrera, M., Berardesca, D., Pinnaro, P., Messina, M., & Arcangeli, G. (2006). A Double-Blind, Vehicle-Controlled Clinical Study to Evaluate the Efficacy of MASO65D (XClair), a Hyaluronic Acid-Based Formulation, in the Management of Radiation-Induced Dermatitis. *Cutaneous and Ocular Toxicology*, 25(3), 165-171.
- Ravo, V., Calvanese, M. G., Di Franco, R., Crisci, V., Murino, P., Manzo, R., . . . Muto, P. (2011). Prevention of cutaneous damages induced by radiotherapy in breast cancer: An institutional experience. *Tumori Journal*, 97(6), 732-736. doi:10.1177/030089161109700609
- Roy, I., Fortin, A., & Larochele, M. (2001). The impact of skin washing with water and soap during breast irradiation: A randomized study. *Radiotherapy and Oncology*, 58, 333-339.
- Schmuth, M., Wimmer, M., Hofer, S., Sztankay, A., Weinlich, G., Linder, D., Elias, P., Fritsch, O., & Fritsch E. (2002). Topical corticosteroid therapy for acute radiation dermatitis: a prospective, randomized, double-blind study. *British Journal of Dermatology*, 146, 983-991.
- Seki, T., Morimatsu, S., & Nagahori, H. (2003). Free residual chlorine in bathing water reduces the water-holding capacity of the stratum corneum in atopic skin. *Journal of Dermatology*, 30(3), 196-202.
- Sitton, E. (1992). Early and Late Radiation-Induced Skin Alterations Part 1: Mechanisms of Skin Changes. *Oncology Nursing Forum*, 19(5), 801-807.
- Su, C., Mehta, V., Ravikumar, L., Shah, R., Pinto, H., Halperin, J., Koong, A., Goffinet, D., & Le, Q. (2004). Phase II Double Blind Randomized Study Comparing Oral Aloe Vera Versus Placebo to Prevent Radiation Related Mucositis in Patients with Head and Neck Neoplasms. *International Journal Radiation Oncology, Biology, & Physics*, 60(1), 171-177.
- Szumacher, E., Wighton, A., Franssen, E., Chow, E., Tsao, M., Ackerman, I., Kim, J., Wojcicka, A., Yee, U., Sixel, K., & Hayter, C. (2001). Phase II study assessing the effectiveness of biafine cream as a prophylactic agent for radiation-induced acute skin toxicity to the breast in women undergoing radiotherapy and concomitant CMF chemotherapy. *International Journal of Radiation Oncology, Biology & Physics*, 51(1), 81-86.
- Theberge, V., Harel, F., & Dagnault, A. (2009). Use of Axillary Deodorant and Effect on Acute Skin Toxicity During Radiotherapy for Breast Cancer: A Prospective Randomized Noninferiority Trial. *International Journal of Radiation Oncology, Biology & Physics*, 75(4), 1048-1052.
- Trueman, E. (2015). Management of radiotherapy-induced skin reactions. *International Journal of Palliative Nursing*, 21(4), 187-192. doi:10.12968/ijpn.2015.21.4.187
- Watson, L., Gies, D., Thompson, E., & Thomas, B. (2012). Randomized Control Trial: Evaluating Aluminum-Based Antiperspirant Use, Axilla Skin Toxicity, and Reported Quality of Life in Women Receiving External Beam Radiotherapy for Treatment of Stage 0, 1, and II Breast Cancer. *International Journal of Radiation Oncology, Biology and Physics*, 83(1), 29-34.
- Wells, M., Macmillan, M., Raab, G., MacBride, S., Bell, N., MacKinnon, K., MacDougall, H., Samuel, L., & Munro, A. (2004). Does aqueous or sucralfate cream affect the severity of erythematous radiation skin reactions? A randomized controlled trial. *Radiotherapy and Oncology*, 73, 153-162.
- Wickline, M. (2004). Prevention and Treatment of Acute Radiation Dermatitis: A Literature Review. *Oncology Nursing Forum*, 31(2), 237-244.
- Williams, M., Burk, M., Loprinzi, C., Hill, M., Schomberg, P., Nearhood, K., O'Fallon, J., Laurie, J., Shanahan, T., Moore, R., Uria, R., Kuske, R., Engel, R., & Eggleston, W. (1996). Phase III Double Blind Evaluation of an Aloe Vera Gel as a Prophylactic Agent for Radiation Induced Skin Toxicity. *International Journal Radiation Oncology, Biology, & Physics*, 36(2), 345-349.

Vuong, T., Franco, E., Lehnert, S., Lambert, C., Portelance, L., Nasr, E., Faria, S., Hay, J., Larsson, S., Shenouda, G., Souhami, L., Wong, F., & Freeman C. (2004). Silver leaf nylon dressing to prevent radiation dermatitis in patients undergoing chemotherapy and external beam radiotherapy to the perineum. *International Journal of Radiation Oncology, Biology, & Physics*, 59(3), 809-814.

## Sleep Wake Disturbances

Beck, S., Schwartz, A., Towsley, G., Dudley, W., & Barsevick, A. (2004). Psychometric evaluation of the Pittsburgh Sleep Quality Index in cancer patients. *Journal of Pain Symptom and Management*, 27(2), 140-148.

Berger, A.M., Parker, K.P., Young – McCaughan, S., Mallory, G.A., Barsevick, A.M., Beck, S.L., et al. (2005). Sleep/wake disturbances in people with cancer and their caregivers: State of the science. *Oncology Nursing Forum*. 32(6), E98 – E126.

Bonnet, M.H., & Arand, D.L. (2013). Treatment of Insomnia. Up-to-date. Retrieved July 20, 2013 from: [http://www.uptodate.com/contents/treatment-of-insomnia?detectedLanguage=en&source=search\\_result&search=insomnia&selectedTitle=1%7E150&provider=noProvider](http://www.uptodate.com/contents/treatment-of-insomnia?detectedLanguage=en&source=search_result&search=insomnia&selectedTitle=1%7E150&provider=noProvider)

Canadian Association of Nurses in Oncology/ Association canadienne des infirmieres en oncologie (CANO/ACIO). Practice Standards and Competencies for the Specialized Oncology Nurse. 2006: 1-47.

Cancer Care Ontario, Nursing Professional Advisory Committee. Fatigue guideline. Telephone Nursing Practice and Symptom Management Guidelines. 2004, Apr 5 [cited 2007 September 4]: 17–18. Available from: <http://www.cancercare.on.ca/documents/NursingTelephonePracticeGuidelines.pdf>

Canadian Association of Psychosocial Oncology & Canadian Partnership Against Cancer. A Pan-Canadian Practice Guideline: Prevention, Screening, Assessment and Treatment of Sleep Disturbances in Adults with Cancer. December 2012. Available from: [http://www.capo.ca/pdf/Sleep\\_Disturbances\\_Guideline\\_Eng.pdf](http://www.capo.ca/pdf/Sleep_Disturbances_Guideline_Eng.pdf)

Cancer Gov. <https://www.cancer.gov/about-cancer/treatment/side-effects/sleep-disorders-hp-pdq>

Clark, J., Cunningham, M., McMillan, S., Vena, C., & Parker, K. (2004). Sleep – wake disturbances in people with cancer part II: Evaluating the evidence for clinical decision making. *Oncology Nursing Forum*, 31(4): 747–768.

Cote, K. Normal sleep and sleep hygiene. Canadian Sleep Society ©. 2004: 1-2. [Cited August 29, 2007]: Available from: [http://www.css.to/sleep/normal\\_sleep.pdf](http://www.css.to/sleep/normal_sleep.pdf)

Davidson, J.R., MacLean, A.W., Brundage, M.D., & Schulze, K. (2002). Sleep disturbance in cancer patients. *Social Science and Medicine*, 54(9), 1309-1321.

Davidson, J.R., Waisberg, J.L., Brundage, M.D., & Maclean, A.W. (2001). Nonpharmacologic group treatment of insomnia: A preliminary study with cancer survivors. *Psycho – Oncology*, 10, 389- 397.

Fraser Health, Hospice Palliative Care Program. Fatigue. Hospice Palliative Care Program Symptom Guidelines. 2006, Dec 5; [cited 2007, September, 4]: 1-15. Available from: <http://www.fraserhealth.ca/NR/rdonlyres/embys6sfngqxxkuzrolqqephv2d35whl3vafxhnrnqqud2ofrrkfvh74syoc2ovupn2bal043ayeqp/11FHSymptomGuidelinesFatigue.pdf>

Fong, E. (2019). Cancer: Evidence Summary. Yoga Therapy for Insomnia. The Joanna Briggs Institute EBP Database, JBI@Ovid. 2019; JBI7017

Fong, E. (2019). MBBS MPHTM. Evidence Summary. Cancer: Cognitive Behavioral Therapy for Insomnia. The Joanna Briggs Institute EBP Database, JBI@Ovid. JB17018

Jacobs, G.D., Pace-Schott, E.F., Stickgold, R., & Otto, M.W. (2004). Cognitive behavior therapy and pharmacotherapy for insomnia. *Archives of Internal Medicine*, 164, 1888–1896.

Matthews, E., Carter, P., Page, M., Dean G., and Berger. Sleep-Wake Disturbances: a Systematic Review of evidence-based interventions for management in patients with cancer. *A Clinical Journal of Oncology Nursing*, 22 (1), p.37-52 <http://dx.doi.org/10.1188/18.CJON.37-52>

Mills M, Graci GM. Sleep Disturbances In: Yarbro CH, Frogge MH, Goodman M, editors. Cancer Symptom Management. 3<sup>rd</sup> ed. Sudbury, Massachusetts: Jones and Bartlett Publishers; 2004. p. 111- 135.

Morin, C.M. Insomnia. Canadian Sleep Society ©. 2004: 1-2. [Cited August 29, 2007]: Available from: <http://www.css.to/sleep/insomnia.pdf>

National Cancer Institute. Sleep Disorders PDQ Health Professional Version. July 2012. Available from: <http://www.cancer.gov/cancertopics/pdq/supportivecare/sleepdisorders/HealthProfessional/page1/AllPages>

National Cancer Institute. Common Terminology Criteria for Adverse Events. Version 4.03. 2010. Available from: [http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE\\_4.03\\_2010-06-14\\_QuickReference\\_8.5x11.pdf](http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf)

Oncology Nursing Society. Sleep – wake disturbances, definitions list. Evidence – Based Practice Resource Area. [Cited August 23, 2007]. Available from: <http://onsopcontent.ons.org/toolits/evidence/Clinical/summaries.html>

Oncology Nursing Society. Sleep – wake disturbances, Evidenced – based summaries. Evidence – Based Practice Resource Area. [Cited August 23, 2007]. Available from: <http://onsopcontent.ons.org/toolits/evidence/Clinical/summaries.html>

Page, M.S., Berger, A.M., & Johnson, L.B. Sleep – wake disturbances: What can nurses do to assist people with cancer with sleep – wake disturbances? Putting Evidence into Practice. Pittsburgh PA, Oncology Nursing Society. 2006: 1-4. [Cited August 23, 2007]. Available from: [www.ons.org/outcomes](http://www.ons.org/outcomes)

Page, M.S., Berger, A.M., & Johnson, L.B. (2006). Putting evidence into practice: Evidence – based interventions for sleep –wake disturbances. *Clinical Journal of Oncology Nursing*, 10(6), 753–767.

Palesh, O.G., Roscoe, J.A., Mustian, K.M., Roth, T., Savard, J., Ancoli-Israel, S., Heckler, C., Purnell, J.Q., Janelsins, M.C., & Morrow, G.R. (2010). Prevalence, demographics, and psychological associations of sleep disruption in patients with cancer: University of Rochester Cancer Center-Community Clinical Oncology Program. *Journal of Clinical Oncology*, 28(2), 292-298.

Savard, J., Simard, S., Ivers, H., & Morin, C.M. (2005). Randomized study on the efficacy of cognitive – behavioral therapy for insomnia secondary to breast cancer, part I: Sleep and psychological effects. *Journal of Clinical Oncology*, 23(25), 6083–6096.

Schutte-Rodin, S., Broch, L., Buysse, D., Dorsey, C., & Sateia, M. (2008). Clinical guideline for the evaluation and management of chronic insomnia in adults. *Journal of Clinical Sleep Medicine*, 4(5), 487-502.

Siversten, B., Omvik, S., Pallesen, S., Bjorvatn, B., Havik, O.E., Kavle, G., et al. (2006). Cognitive behavioral therapy vs zopiclone for treatment of chronic primary insomnia in older adults. *Journal of the American Medical Association*, 295(24), 2851–2858.

Up-to-Date. (2019). Overview of the treatment of insomnia in adults. Medication Side Effects. Retrieved from: <https://www.uptodate.com/contents/overview-of-the-treatment-of-insomnia-in-adults>

Vena, C., Parker, K., Cunningham, M., Clark, J., & McMillan, J. (2004). Sleep – wake disturbances in people with cancer part I: An overview of sleep, sleep regulation, and effects of disease and treatment. *Oncology Nursing Forum*, 31(4), 735–746.

Wang, M.Y., Wang, S.Y., & Tsai, P.S. (2005). Cognitive behavioural therapy for primary insomnia: A systematic review. *Journal of Advanced Nursing*, 50(5), 553–564.

Woodward, S. C. (2011). Cognitive-behavioural therapy for insomnia in patients with cancer. *Clinical Journal of Oncology Nursing*, 15(4), E42-52.

Young Adult Cancer. <https://www.youngadultcancer.ca/dr-sheila-garlands-guide-to-better-sleep-habits/>

## Xerostomia

Bartels, C. (2018). Xerostomia: helping patients with dry mouth. The Oral Cancer Foundation. Retrieved August 28, 2019 from: <https://oralcancerfoundation.org/complications/xerostomia/>

Beck, S. Mucositis. In: Yarbro CH, Frogge MH, Goodman M, editors. *Cancer Symptom Management*. 3<sup>rd</sup> ed. Sudbury, Massachusetts: Jones and Bartlett Publishers; 2004, p. 276–292.

Berk, L.B., Shivnani, A.T., & Small, W. (2005). Pathophysiology and management of radiation – induced xerostomia. *Journal of Supportive Care*. 3(3);191–200.

Bruce, S.D. (2004). Radiation – induced xerostomia: How dry is your patient? *Clinical Journal of Oncology Nursing*, 8(1), 61–67.

Canadian Association of Nurses in Oncology/ Association canadienne des infirmières en oncologie (CANO/ACIO). Practice Standards and Competencies for the Specialized Oncology Nurse. 2006: 1-47.

Cancer Care Ontario, Nursing Professional Advisory Committee. Oral stomatitis/mucositis guideline. Telephone Nursing Practice and Symptom Management Guidelines. 2004, Apr 5 [cited 2007 April 17]: 23-24. Available from: <http://www.cancercare.on.ca/documents/NursingTelephonePracticeGuidelines.pdf>

Center for Scientific Information. (2018). American Dental Association. Oral health topics. Cannabis: Oral health effects. Retrieved August 28, 2018 from <https://www.ada.org/en/member-center/oral-health-topics/cannabis>

Chambers, J.S., Garden, A.D., Kies, M.S., & Martin, J.W. (2004). Radiation – induced xerostomia in patients with head and neck cancer: Pathogenesis, impact on quality of life, and management. *Head & Neck*, 26(9), 796-807.

Chambers, J.S., Rosenthal, D.I., & Weber, R.S. (2007). Radiation – induced mucositis. *Head & Neck*. 29(1), 58–63.

Cotomacio, C., Campos, L., Simoes, A., Jaguar, G., Crosato, E., & Alves, F. (2017). Influence of bethanechol on salivary parameters in irradiated patients. *Medicina Oral*, 22 (1), pp. e76-e83. Doi: [10.4317/medoral.21395](https://doi.org/10.4317/medoral.21395)

DynaMed. (2013, April7). *Xerostomia*. Ipswich, MA:EBSCO Publishing. Retrieved April 15, 2013, from: <http://web.ebscohost.com/dynamed/detail?sid=5445a38b-469f-434a-a495-eef7e13e205f%40sessionmgr113&vid=1&hid=103&bdata=JnNpdGU9ZHluYW1lZC1saXZlJnNjb3BIPXNpdGU%3d#db=dme&AN=576492>

Dirix, P., Nuyts, S., & Van den Bogaert, W. (2006). Radiation – induced xerostomia in patients with head and neck cancer: A literature review. *Cancer*, 107(11), 2525–2534.



Fulton, J.S., Middleton, G.J., & McPhail, J.T. (2002). Management of oral complications. *Seminars in Oncology Nursing*. 18(1), 28-35.

Galloway, T., & Amdur, R. (2018). Management and prevention of complications during initial treatment of head and neck cancer. UpToDate. Retrieved August 28, 2018 from: [https://www.uptodate.com/contents/management-and-prevention-of-complications-during-initial-treatment-of-head-and-neck-cancer?search=oral%20rinses%20xerostomia&source=search\\_result&selectedTitle=6~150&usage\\_type=default&display\\_rank=6#H7](https://www.uptodate.com/contents/management-and-prevention-of-complications-during-initial-treatment-of-head-and-neck-cancer?search=oral%20rinses%20xerostomia&source=search_result&selectedTitle=6~150&usage_type=default&display_rank=6#H7)

Johnstone, P., Peng, P., May, B., Inouye, W., & Niemtzw, R. (2001). Acupuncture for pilocarpine-resistant xerostomia following radiotherapy for head and neck malignancies. *International Journal of Radiation Oncology*, 50 (1)

Maher, K. Xerostomia. In: Yarbro CH, Frogge MH, Goodman M, editors. *Cancer Symptom Management*. 3<sup>rd</sup> ed. Sudbury, Massachusetts: Jones and Bartlett Publishers; 2004. P. 215-229.

Main, B.E., Calman, K.C., Ferguson, M.M., Kaye, S.B., MacFarlane, T.W., Mairs, R.J., Samaranayake, L.P., Willox, J., & Welsh, J. (1984). The effect of cytotoxic therapy on saliva and oral flora. *Oral Surgery, Oral Medicine, and Oral Pathology* 58(5), p. 545.

Miller, M., & Kearney, N. (2001). Oral care for patients with cancer: A review of the literature. *Cancer Nursing*. 24(1), 241–254.

National Cancer Institute, US National Institute of Health. Oral complications of chemotherapy and head/neck radiation (PDQ®) – Health Professional Version. Available from: <http://www.cancer.gov/cancertopics/pdq/supportivecare/oralcomplications/HealthProfessionals>

National Institute of Health & National Cancer Institute (2010). Common Terminology Criteria for Adverse Events. Available from : [http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE\\_4.03\\_2010-06-14\\_QuickReference\\_8.5x11.pdf](http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf)

National Oncology Alliance. Xerostomia. NOA Treatment Guidelines. 2006; 1: 1-3. Available from: [http://guidelines.noainc.com/documents/Guidelines/Xerostomia\\_Guideline.pdf](http://guidelines.noainc.com/documents/Guidelines/Xerostomia_Guideline.pdf)

Negrin, R.S., Bedard, J.F., & Toljanic, J.A. (2013). Oral toxicity associated with chemotherapy. In: D.S. Basow (Ed.), *UpToDate*. Waltham, MA: UpToDate. Retrieved April 30, 2013 from: [http://www.uptodate.com/contents/oral-toxicity-associated-with-chemotherapy?source=search\\_result&search=oral+toxicity+associated+with+chemotherapy&selectedTitle=1%7E150](http://www.uptodate.com/contents/oral-toxicity-associated-with-chemotherapy?source=search_result&search=oral+toxicity+associated+with+chemotherapy&selectedTitle=1%7E150)

Teguh, D.N et al. (2009). Early hyperbaric oxygen therapy for reducing radiotherapy side effects: Early results of a randomized trial in oropharyngeal and nasopharyngeal cancer. *International Journal of Radiation Oncology*, 75 (3), pp.711-716. Retrieved August 28, 2018 from [https://www.sciencedirect.com/science/article/pii/S0360301608038303?\\_rdoc=1&fmt=high&origin=gateway&docanchor=&md5=b8429449ccfc9c30159a5f9aeaa92ffb](https://www.sciencedirect.com/science/article/pii/S0360301608038303?_rdoc=1&fmt=high&origin=gateway&docanchor=&md5=b8429449ccfc9c30159a5f9aeaa92ffb)

Villa, A., Connell, C. L., & Abati, S. (2015). Diagnosis and management of xerostomia and hyposalivation. *Therapeutics and Clinical Risk Management*, 11, 45–51. <http://doi.org/10.2147/TCRM.S76282>

Wong, R., et al. (2015). Acupuncture-like transcutaneous electrical nerve stimulation versus pilocarpine in treating radiation induced xerostomia: results of RTOG 0537 Phase 3 study. *International Journal of Radiation Oncology*, 92 (2), pp. 220-227. Doi: <https://doi.org/10.1016/j.ijrobp.2015.01.050>